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ABSTRACT
Human chromosome 15q11-q13 contains a cluster of imprinted genes that are associ-
ated with a number of neurological disorders that exhibit non-Mendelian patterns of in-
heritance, such as Angelman syndrome (AS) and Prader-Willi syndrome. Angelman syn-
drome is caused by the loss-of-expression of maternally inherited ubiquitin E3A protein
ligase gene (UBE3A). Prader-Willi syndrome is caused by loss-of-function of paternally
inherited SNORD116 snoRNAs (small nucleolar RNAs), which are expressed as part of
a long polycistronic transcriptional unit (PTU) comprised of SNURF-SNRPN, additional
orphan C/D box snoRNA clusters, and the UBE3A antisense transcript (UBE3A-AS). The
full-length transcript of PTU, including UBE3A-AS, is only expressed in neurons caus-
ing the imprinting of paternal UBE3A. Why this occurs in only neurons remains largely
unknown. Furthermore, this neuron-specific imprinting adds additional difficulty for ther-
apeutic intervention. In this dissertation, the imprinting mechanism ofUBE3A is examined
in detail, while an alternative high-throughput screening (HTS) method for drug discovery
in neurons is developed.
A combination of bioinformatic and molecular analysis of the human and mouse PTU
revealed that UBE3A-AS/Ube3a-AS is extensively processed via 5’ capping, 3’ polyadeny-
lation and alternative splicing, suggesting that the antisense may have regulatory functions
apart from imprinting UBE3A in neurons. Following this discovery, the transcripional
profiles and processing of mouse paternal Ube3a was investigated as literature suggested
that imprinted paternal Ube3a, unlike other imprinted genes, was transcribed up to in-
tron 4. This analysis unveiled a fourth Ube3a isoform that terminates within intron 4.
Moreover, expression of this isoform correlated with Ube3a-AS expression, suggesting al-
ternative reasons for the imprinting of Ube3a. In addition to the analysis of the imprinting
ii
of Ube3a, an alternative solution for drug discovery for central nervous system disorders
was developed and validated. Here, an embryonic stem cell-derived neuronal culture sys-
tem was developed for HTS and tested using the paternal Ube3aY FP reporter cell-line.
Using a known reactivator of paternal Ube3a, Topotecan - a topoisomerase inhibitor, as a
positive control a proof-of-concept study demonstrated the utility of this method for HTS
drug discovery. Collectively, these results advance the field and understanding of antisense
lncRNAs and provide a versatile tool for drug discovery for neurological disorders.
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1. UBE3A IMPRINTING IN NEURONS: A UNIQUE MODEL FOR ANTISENSE
LNCRNA REGULATION
The genomic instability of chromosome 15q11-q13 results in multiple disorders, two
of which seems to be linked to ubiquitin ligase E3A protein (UBE3A) expression, also
known as E6AP, [1–4]. The non-Mendelian inheritance of these disorders are a result of
genomic imprinting, an epigenetic phenomenon that results in the differential expression
of diploid alleles in a parent-of-origin specific manner [5]. With respect to UBE3A, it is
clear that expression and dosage levels are important for human brain development and
functionality. As such, the unique imprinting of UBE3A in only neurons is perplexing.
Although it is possible that the imprint could be an innocent bystander, the fact that it has
been evolutionarily constrained for over 100 million years suggests otherwise [6]. The
focus of this review is to examine the functional significance of the imprinting mechanism
of UBE3A and the roles antisense long non-coding RNA (lncRNA) play in regulation of
the sense transcripts.
1.1 Diseases of Chromosome 15q11-q13
The long arm of human chromosome 15 is characterized by relatively frequent chro-
mosome rearrangements, which are due to low-copy repeat elements at two proximal and
one distal region of the 15q11-q13 region [7–10]. Figure 1.1 depicts the breakpoint
locations around the HERC2 (HECT, homologous to the E6AP carboxyl terminus, and
RDL, regulator of chromosome condensation 1 (RCC1) like domain, domain containing
E3 ubiquitin protein ligase 2) duplicons and the percentage of usages within the large-scale
deletions. This instability results in multiple structural abnormalities, including deletions,
duplications, and translocations [1, 11–14] resulting in three distinct neurodevelopmental
disorders: Prader-Willi syndrome (PWS), Chromosome 15q11-q13 Duplication syndrome
1
(Dup15q) and Angelman syndrome (AS).
1.1.1 Prader-Willi Syndrome
Prader-Willi syndrome (OMIM #176270) is characterized by neonatal hypotonia and
failure to thrive, hyperphagia in early childhood leading to obesity, hypogonadism, short
stature, behavior problems, and mild to moderate intellectual disability [15, 16]. The ge-
netic or epigenetic mutations causing PWS are associated with the specific loss of paternal
expression of the box C/D small nucleolar RNAs (snoRNAs) generated from SNORD116
cluster (previously referred as HBII-85) in the brain [17–19]. The spectrum of mutations
causing PWS include: (i) paternal interstitial deletions of 15q11-q13 region, (ii) maternal
uniparental disomy of chromosome 15, (iii) genomic imprinting defects of the region, or
(iv) loss-of-function mutations in SNORD116 gene cluster [15].
1.1.2 Chromosome 15q11-q13 Duplication Syndrome
Chromosome 15q11-q13 duplication syndrome (OMIM #608636) is characterized by
developmental delay, intellectual disability, early central hypotonia, seizures, and social
impairment [20]. Additionally, duplication of 15q11-q13 is one of the most common
genetic mutations observed in individuals diagnosed with autism spectrum disorder [4,20–
23]. Chromosome 15q duplication syndrome is primarily caused by maternal duplications
of chromosome 15q11-q13 [20, 24]. Currently, Dup15q is known to occur via one of two
ways: interstitial duplication of 15q, or extra isodicentric chromosome of 15q [20,25]. As
the neurodevelopmental disorder is caused by maternal inheritance of duplications, it is
linked to the overexpression of ubiquitin ligase E3A protein (UBE3A) [4].
1.1.3 Angelman Syndrome
Angelman syndrome (OMIM #105830) is a debilitating neurodevelopmental disorder








































































































































smiling and inappropriate laughter [26]. Although clinically distinct, AS shares a com-
mon pathogenesis with Dup15q, namely dysregulation of UBE3A protein. In contrast
to Dup15q, the genetic or epigenetic mutations causing AS are associated with the spe-
cific loss of maternal expression of UBE3A protein in the brain [2, 3, 26]. The spectrum
of mutations causing AS include: (i) maternal interstitial deletions of 15q11-q13 region,
(ii) paternal uniparental disomy of chromosome 15, (iii) genomic imprinting defects of
15q11-q13, or (iv) loss-of-function mutations in the UBE3A gene [26].
1.2 Ubiquitin Ligase E3A Protein Gene
The UBE3A gene is located within the 15q11-q13 imprinted domain and encodes an
E3 ubiquitin-protein ligase that is a central component of the ubiquitin proteasome system
involving the successive action of E1 (ubiquitin-activating), E2 (ubiquitin-conjugating),
and E3 ubiquitin-protein ligases activities [27, 28]. The UBE3A protein is a unique ligase
as it can catalyze the formation of isopeptides via its HECT domain without the help of
E2 proteins. In addition, UBE3A has been shown to function as a typical ubiquitin ligase
and a transcriptional coactivator of steroid hormone receptors [29,30]. Thus far, numerous
cellular proteins have been shown to interact directly or indirectly with UBE3A suggesting
that is has diverse cellular functions (APPENDIX A, Tables A.1, A.2 and A.3).
1.2.1 UBE3A in Neurons
The non-Mendelian inheritance pattern of AS is due to genomic imprinting of UBE3A
[2, 3]; however, UBE3A, unlike most imprinted genes, is expressed from both parental
alleles in almost all cell types except for neurons [31–34]. Expression of the paternal
UBE3A allele in neurons is inhibited by the antisense expression of a long polycistronic
transcriptional unit that is comprised of SNURF-SNRPN, clusters of C/D box snoRNAs
(SNORD116 and SNORD115), and UBE3A antisense transcript (UBE3A-AS) [31, 33, 35–
37]. Figure 1.2 shows the polycistronic transcriptional unit transcribed from the paternal
4
allele (blue) with the overlapping antisense transcript silencing UBE3A (black).
1.3 Genomic Imprinting
Mammals are diploid organisms that inherit a chromosome set from each parent. As a
result, the majority of genes are expressed from both parents; however, a subset of genes
show parent-specific gene expression due to epigenetic modifications. Figure 1.3 depicts
normal biallelic expression compared to the monoallelic expression of imprinted genes.
There are over a 100 of these imprinted genes in mouse and humans [38,39]; the majority
of which are found within gene clusters that house at least one non-coding RNA and
several protein coding genes.
1.3.1 Imprinting Control Regions
Epigenetics is defined as heritable modifications of the genome that are not genetic
changes (e.g. DNA and chromatin modifications) [40]. As imprinting is an epigenetic
phenomenon, the imprinted genes must be able to acquire modifications, maintain im-
printing status, and be re-established in the germline. For imprinted gene clusters, large-
range cis-acting imprinting control regions (ICRs) are responsible for acquiring parental
modification and maintaining imprinting status [41–43]. All ICRs have differential DNA
methylation regions (DMR), which carry parental information [44].
The ICR for PWS and AS has a bipartite structure comprising the Prader-Willi and
Angelman syndrome imprinting centers (PWS-IC and AS-IC); thus, giving this ICR bidi-
rectional control of the cluster of imprinted genes in the 15q11-q13 region [45]. The PWS-
IC is a positive regulatory element responsible for the establishment and maintenance of
paternal gene expression [46], while AS-IC negatively regulate PWS-IC on the maternal
chromosome [47].
Differential methylation is associated with a CpG island surrounding the promoter and



































































































































































































































































































Figure 1.3: The majority of genes show biallelic expression with maternal (red) and pater-
nal (blue) alleles expressed in all tissues. In a subset of genes via some epigenetic mecha-
nism such as DNA methylation, gene expression is limited to monoallelic expression..
is methylated ICR, and. is unmethylated ICR.
methylated on the maternal chromosome, and is almost completely unmethylated on the
paternal chromosome [49,50]. The AS-IC on the maternal allele confers DNAmethylation
and suppression of PWS-IC, but is methylated and inactive on the paternal allele. This
results in PWS-IC regulation of the majority of the genes as paternal expression except for
UBE3A and ATP10A, which are maternally expressed [47, 51].
1.4 Function of Imprinting
No matter the theory, the overall result of imprinting is the differential silencing of
alleles. This imprinting does not happen by chance as it is often evolutionary conserved
between mouse and humans. For example, the imprinted cluster within 15q11-q13 arose
105-180 million years ago [6]; and despite the disease phenotypes and genomic instability
associated with the region, it remains conserved. For some reason, it is advantageous
to imprint this gene cluster and many others. One method to explore what makes the
imprinting of gene clusters advantageous, is to investigate the function of the imprinted
genes. Are the genes dosage sensitive? Does the imprint increase regulatory function? For
the 15q11-q13 imprinting cluster, these answers are not readily apparent.
7
1.4.1 Dosage Regulation
Why Ube3a became imprinted in neurons is unclear. The current theory is that Ube3a-
AS evolved to reduce Ube3a expression in neurons to regulate dosage because termination
of Ube3a-AS leads to increased levels of Ube3a expression in the brain [36,52,53]. When
our laboratory rigorously tested this theory, we determined that the function of the im-
printing mechanism was not to reduce the expression of Ube3a in the brain, as there was
no correlation between the imprint and expression levels of Ube3a/UBE3A in mouse and
human [54]. Additionally, while the paternal Ube3a allele was silenced, the maternal
allele was upregulated during development so that overall Ube3a expression remained un-
changed [54]. Altogether, the findings suggest that imprinting of Ube3a in neurons may
have evolved for reasons other than to reduce Ube3a expression in neurons.
1.4.2 Regulatory Function
The evolution of SNRPN is a good example of a duplication event leading to tissue-
specific imprinting with alternative function from its ancestor gene, SNRPB/B. Studies
have shown that Snrpn originated from Snrpb, a small nuclear ribonucleoprotein (snRNP)
gene encoding for SmB in mice, locus via a duplication event about 180-210 million years
ago [6, 55]. While SmB is replaced by SmN in the brain, SNRPB/B is upregulate in the
absence of SNRPN suggesting that the two genes are tightly regulated [55, 56]. Despite
their similarities, SNRPB/B and SNRPN have distinct snRNP association along with tissue-
specific expression, suggesting that SNRPN has evolved an alternative function compared
to its ancestral gene [57].
Given the current findings, Ube3a does not appear to be imprinted as a mechanism to
regulate dosage in neurons. With that in mind, it is possible that Ube3a is imprinted in
neurons because of additional regulatory functions. While Ube3a is highly expressed in
the brain, the imprint has no effect on overall expression [54]. Therefore, it is unlikely
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that the imprint of Ube3a is directly linked to Ube3a protein expression; however, its long
non-coding antisense RNA transcript, Ube3a-AS, arises only in neurons as part of the
imprinting mechanism of Ube3a. Further study of this transcript may reveal the functional
reason for imprinting Ube3a in neurons.
1.5 Long Non-Coding RNA
Over the last few decades, the scientific community has increasingly become fascinated
with non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNA), and with
good reason. With the advancement of genomic sequencing technologies, numerous an-
notations and deep sequencing from multiple species have demonstrated that ncRNAs are
more abundant than protein-coding genes [58, 59]. To put this in perspective, of the 75-
90% of the human genome that is transcribed, only 3% is protein-coding [60–64]. More
importantly, this is not transcriptional noise as these ncRNAs perform a myriad of func-
tions by interacting with DNA, RNA, and proteins similar to protein-coding genes [65,66].
The importance of ncRNAs extends to genomic imprinting as well since all ICRs have at
least one lncRNA expressed from the unmethylated parental chromosome [67–69]. Even
with the clear importance of ncRNA, the function of the majority of ncRNAs, especially
lncRNAs, is unknown.
Recently, the importance of ncRNAs in tissue- and developmental stage-specific gene
expression has been extensively explored. Moreover, increasing evidence implements
them in brain development, synaptic plasticity, and neurological disease, with the highest
proportion of tissue-specific lncRNA expression in the brain [70, 71]. Long non-coding
RNAs are less understood. With no common sequence or structure, classification is dif-
ficult. In general, lncRNA preform many similar roles as ncRNAs, like microRNAs and
small interfering RNAs, and are separate from ncRNAs via size (> 200 bp). A simplistic
classification of lncRNAs uses loci-of-origin resulting in several different categories, three
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Figure 1.4: Schematic of lncRNAs based on loci-of-origin depicting an enhancer RNA,
sense and antisense overlapping RNAs, and an intergenic RNA.
of which, enhancer RNAs, overlapping RNAs, and intergenic RNAs, are depicted in Fig-
ure 1.4. These three types of lncRNA are all present within ICRs [72–76], with some of
the most well-studied lncRNAs in ICRs being antisense lncRNA.
1.6 Antisense lncRNA
Natural antisense transcripts are endogenous transcripts with complete or partial over-
lap of genes or ncRNA that can work in cis or trans. Sense/antisense pairings can be
non-coding or protein-coding; however, the majority of pairs are non-coding antisense
regulating protein-coding sense [74]. Of the protein-coding sense transcripts, a major-
ity ( 70%) have antisense pairings, many of which are lncRNAs [77, 78]. Furthermore,
sense/antisense origination is more likely to be conserved than gene pairs on the same
strand, suggesting a conserved functional significance [79]. This functional conservation
is observed in their diverse structure, expression pattern, and methods of regulation [80],
such as direct regulation of transcription (i.e. transcriptional interference), epigenetic reg-
ulation (i.e. genomic imprinting), nucleus interactions (i.e. alternative splicing and termi-
nation), and cytoplasmic interaction (i.e. mRNA stability and masking microRNA binding
sites).
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Figure 1.5: FGFR2-AS plays a central role in tissue-specific alternative splicing of FGFR2
via chromatin remodeling. The FGFR2 antisense transcript recruits PRC2 and KDM2a,
which interfere with PTB repression of exon IIIb, resulting in exclusion of exon IIIc. PolII,
polymerase II, antisense in red and sense strand in blue.
1.6.1 FGFR2-AS
Antisense transcript of FGFR2 (FGFR2-AS), human fibroblast growth factor receptor
2, is a recently discovered antisense lncRNA of approximately 875 bp that starts 282 bp
upstream exon IIIc of FGFR2 gene [81]. FGFR2 exhibits chromatin to tissue-specific al-
ternative splicing via a chromatin-splicing adaptor system (MRG15), which recognizes
H3K36me2,3 to inhibit inclusion of alternative splicing exon IIIb, and protein-protein
interaction recruiting PTB (polypyrimidine tract binding protein) to exon IIIb (negative
splicing regulatory element) [82, 83]. Only recently has FGFR2 been shown to have an
antisense transcript that does not appear to be spliced or polyadenylated [81]. Gonzalez
et al. determined that this evolutionary conserved antisense transcript is located predom-
inantly in the nucleus, where it plays a role in alternative splicing of FGFR2 sense gene.
Additionally, the group demonstrated that FGFR2-AS inhibits repression of exon IIIb by
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Figure 1.6: Transcription of AIRN regulates transcriptional gene silencing of the IGF2R
gene cluster. Continuous AIRN transcription silences IGF2R by transcriptional overlap
of IGF2R promoter. By some unknown mechanism, the IGF2R promoter is irreversibly
methylated. Silencing of SLC22A2 and SLC22A3 occurs through AIRN-mediated recruit-
ment of chromatin modifiers to their promoters. Maternal allele (red), paternal allele
(blue), silenced genes (gray), and non-imprinting genes (white). Arrows denote direction
of transcription.
interfering with PTB recruitment as shown in Figure 1.5. In doing so, FGFR2-AS recruits
PRC2 (polycomb repressive complex 2) and KDM2a, a histone demethylase, to modulate
splicing. Furthermore, demonstrating that this process is dependent on chromatin remod-
eling suggesting a central role in tissue-specific alternative splicing for FGFR2-AS.
1.6.2 Airn
Airn (antisense to Igf2r RNA non-coding), a 108 kbp paternally expressed lncRNA, is
responsible for the silencing of the three maternally expressed protein-coding genes, Igf2r,
Slc22a2, and Slc22a3 within the Igf2r gene cluster. Expression of Airn is responsible for
the silencing of overlapping Igf2r and non-overlapping Slc22a2 and Slc22a3 in cis [69]
as shown in Figure 1.6. For Slc22a2 and Slc22a3, Airn recruits chromatin modifiers in a
sequence-specific manner to their promoters [84]. Interestingly, Airnmust be continuously
transcribed to silence overlapping Igf2r until the Igf2r promoter is irreversibly silenced by
CpG methylation, which is sufficient to maintain the imprint [85,86]. How chromatin and
DNA modifiers are recruited to the Igf2r promoter, and what role the antisense transcript
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Figure 1.7: Nespas overlapping transcription occludes the Nesp promoter, promoting CpG
methylation silencing paternal expression of Nesp. Maternal allele (red), paternal allele
(blue), silenced genes (gray). Arrows denote direction of transcription. Zoom view of
overlapping exons of Nesp and Nespas.
plays, if any, in its recruitment remains unclear.
1.6.3 Nespas
Nespas, a 27 kbp lncRNA, is a paternally expressed antisense lncRNA belonging to
the Gnas imprinting cluster containing four sense transcripts: Nesp, Gnasxl, Exon1A, and
Gnas [87–90]. Nesp is maternally expressed in all tissues [91, 92], and imprinted ex-
pression is controlled by paternally methylated Nesp DMR and maternally methylated
Nespas-Gnasxl DMRs, which contains promoters for Nespas and Gnasxl [93, 94]. The
paternal restricted expression of Nespas is due to methylation of the maternal Nespas pro-
moter [95,96]. Figure 1.7 depicts the silencing of paternal Nesp via Nespas transcriptional
overlap of the Nesp promoter resulting in the recruitment of H3K4me3, which methylates
the Nesp promoter [90, 97–100].
1.6.4 Nudt6
Nudt6 (nudix[nucleoside diphosphate linked moiety X]-type motif 6), also known
as Fgf-2 antisense transcript (Fgf2-AS), a protein-coding gene belonging to the cytoso-
lic Nudix hydrolase gene family, is the transcribed antisense to Fgf-2, a heparin-binding
growth factor involved in multiple physiological processes including cortical neurogene-
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sis [101]. Nudt6 has multiple isoforms localizing to mitochondria, nucleus and cytoplasm,
with four of the isoforms producing proteins between 18 - 35 kDa [102]. The evolu-
tionary conserved Fgf-2/Nudt6 locus shows reciprocal expression that is tightly balanced
via chromatin remodeling factors [103, 104]. Additionally, the partial overlap of Fgf-2 3’
UTR (untranslated region) can inhibit Fgf-2 mRNA expression in the absence of Nudt6
translation by initiating Ago2-dependent pathways, reducing Fgf-2 mRNA stability and
translation efficiency [105] as shown in Figure 1.8. Altogether, Nudt6 demonstrates both
protein-coding and lncRNA function.
Figure 1.8: The partial overlap of FGF-2 by the protein-coding gene NUDT6 regulates
FGF-2 expression by forming double-stranded RNA duplexes reducing stability and trans-
lation efficiency. Arrows denote direction of transcription.
1.6.5 Kcnq1ot1
Kcnq1ot1, also known as Lit1, is a 92 kbp lncRNA that emerges from intron 11 of
Kcnq1 [106, 107]. The Kcnq1 imprinting cluster encompasses 10-12 imprinted mater-
nally expressed protein-coding genes. Figure 1.9 shows that methylation of the mater-
nal Kcnq1ot1 promoter restricts expression of the antisense lncRNA to the paternal al-
lele [108]. Currently, there are two hypotheses for the imprinting mechanism of the Kcnq1
imprinting cluster: (1) direct silencing by Kcnq1ot1 recruits and propagates repressive fac-
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Figure 1.9: Long range silencing of the KCNQ1 imprinting gene cluster is due to
KCNQ1OT1. It is proposed that processing of KCNQ1OT1 results in small regulatory
RNAs, which interact with the imprinted genes causing silencing. Maternal allele (red),
paternal allele (blue), silenced genes (gray), and non-imprinted genes (white). Arrows
denote the direction of transcription.
tors [109], (2) the regulatory elements produced by the transcription of Kcnq1ot1 recruits
and propagates chromatin repressive factors [110,111]. While there is evidence to support
both hypotheses, recent work by Schultz et al. suggest that it is the regulatory elements
generated from the transcription of Kcnq1ot1 that are responsible for silencing the Kcnq1
imprinting cluster [112].
By integrating publicly available sequencing data for the Kcnq1ot1 region, Schultz
et al. observed extensive processing of Kcnq1ot1 resulting in enhancer- and promoter-
associating RNAs. These sequences line up to the poly(A)-sequencing sites observed
in the mm9 UCSC genome assembly [113] generated at Merck Research Laboratories.
Additionally, Schultz et al. confirmed multiple independent ncRNAs transcribed from the
Kcnq1ot1 region using a combination of 5 rapid amplification of cDNA ends (RACE) and
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chromosome conformation capture (3C) assay, and demonstrated that at least one of these
RNAs directly interacted with the Kcnq1 promoter in the heart. Furthermore, when this
transcription-rich region was deleted, imprinting was lost in the Kcnq1 imprinting cluster,
altogether suggesting the region acts as a long-distance silencer.
1.6.6 BACE1-AS
The antisense transcript of BACE1 (BACE1-AS), a2 kbp lncRNA, is transcribed from
the BACE1 gene (beta-site amyloid precursor protein (APP)-cleaving enzyme 1), which
is central to the pathogenesis of Alzheimer’s disease. The lncRNA is a fully processed
transcript that is highly expressed in Alzheimer’s affected brains with two polyadenylated
splice variants observed in human and mouse [114]. Additionally, BACE1-AS prevents
microRNA-induced translational repression by competing with miR-485-5p binding of
BACE1 in a tightly regulated system for BACE1 protein [115]. When BACE1-AS binds
to BACE1, it forms double-stranded RNA (dsRNA) duplexes that increase the stability
of BACE1 as shown in Figure 1.10. As a result, elevated levels of BACE1-AS increase
BACE1 expression creating a post-translational feed forward loop.
Figure 1.10: BACE1-AS increases stability of BACE1 via dsRNA duplexes. This in-
crease in BACE1 stability results in increased protein levels of BACE1 creating a post-
translational feed forward loop. Arrows denote the direction of transcription.
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1.6.7 BDNF-AS
The antisense transcript to brain-derived neurotrophic factor (BDNF-AS) is a 191 kbp
transcript with twelve splicing variants [116]. The first four exons of BDNF-AS are down-
stream BDNF, while the remaining exons overlap coding and introns of BDNF [116]. The
BDNF gene, which plays an important role in peripheral neurons, neuron size, and arbori-
sation, is a complex gene with 11 exons and 9 unique promoters resulting in 17 spliced
transcripts with different 5’ and 3’ UTRs [116, 117]. The partially conserved antisense
transcript forms dsRNA duplexes with BDNF mRNA in the brain resulting in the recruit-
ment of EZH2 (enhancer of zeste homolog 2) and PRC2 to the promoter of BDNF [117]
as depicted in Figure 1.11. Thus, knockdown of the antisense results in increased mRNA
and protein levels of BDNF.
Figure 1.11: BDNF-AS regulates BDNF gene expression by forming double-stranded RNA
resulting in the recruitment of chromatin modeling factors to the promoter of BDNF. Ar-
row denotes the direction of transcription.
1.6.8 Ube3a-AS
The Ube3a antisense transcript is a part of a paternally expressed large transcriptional
unit (> 1000 bp) that initiates upstream of the PWS-IC from the Snurf/Snrpn promoter
[31,33]. An unusual result of Ube3a-AS being a part of this large transcriptional unit is its
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lack of a unique promoter. As such, its regulatory control for neuronal specific expression
remains unclear. Moreover, how or why Ube3a-AS regulates Ube3a is still a mystery
as very little is known about Ube3a-AS, besides the fact that it is sufficient to imprint
Ube3a [35, 118, 119].
There is no methylation at the promoter of Ube3a or anywhere else within paternal
Ube3a [118, 120, 121]. In fact, paternal Ube3a has been shown to be expressed; its tran-
scription terminates between exon 4 and 5 [36, 122]. Although paternal Ube3a is not
currently known to produce a transcript, this partial expression is in stark contrast to the
other well-studied antisense lncRNAs. One explanation of Ube3a sense/antisense expres-
sion is that the transcriptional machinery for both transcripts collide causing transcription
to terminate between exon 4 and 5 [36]. In this model depicted in Figure 1.12A,Ube3a-AS
transcription would generate high levels of torsional stress leading to stalling of transcrip-
tional elongation complexes and silencing of Ube3a.
With this model, it would be expected that transcription would stall at different places
throughout Ube3a; however, this is not the case. In two independent studies, biallelic
expression of Ube3a ends at one specific location [36, 122]. Additionally, Numata et
al. demonstrated Ube3a-AS expression upstream Ube3a using their SNP analysis, which
indicates that Ube3a-AS continues transcription beyond the suggested collision point.
The termination of Ube3a-AS upstream Ube3a aligns with polyadenylation sites from
Merck Research Laboratories poly(A)-sequencing data observed in mm9 UCSC Genome
Browser [113]. Moreover, the transcriptional termination of biallelic expression of Ube3a
also aligns with Merck poly(A)-sequencing data. Altogether, these observations suggest
an alternative mechanism of silencing, where the transcription of Ube3a-AS leads to alter-
native polyadenylation within the intron between exon 4 and 5 of Ube3a that terminates
transcription shown in Figure 1.12B.
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Figure 1.12: UBE3A-AS regulates paternal UBE3A expression in neurons. A) Transcrip-
tional collision model for UBE3A-AS regulation of UBE3A. B) Purposed alternative splic-
ing model for UBE3A-AS regulation of UBE3A. Polymerase II (Pol II), antisense Pol II in
red and sense Pol II in blue. Arrows denote the direction of transcription.
1.7 Concluding Remarks
This paper has reviewed the importance of UBE3A and suggested a possible function
for its antisense transcript outside of imprinting of UBE3A as a reason for its imprinting.
Recent studies in our laboratory have demonstrated that Ube3a is not imprinted to regulate
its gene expression in neurons [54]. Moreover, the imprinting of Ube3a has no overall
effect on Ube3a expression suggesting that the importance of imprinting Ube3a may lie
in its antisense transcript, Ube3a-AS [54]. Long non-coding RNAs, like Ube3a-AS, are
diverse in structure and function. It is possible that Ube3a-AS also functions in a complex
manner. It is clear from this review that more investigation is needed to elucidate Ube3a-
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AS function and its connection to Ube3a imprinting.
The implications of UBE3A-AS having a function impacts therapeutic intervention
for the diseases of the area, Angelman syndrome, Prader-Willi syndrome and Chromo-
some15q duplication syndrome. Specifically, for AS where the only current treatment
options target the reactivation of paternal UBE3A via disruption of UBE3A-AS [36, 52,
123–127], any possible function of the antisense transcript will need to be extensively
considered. As such, a better understanding of imprinting of UBE3A may help facilitate
drug development for Angelman syndrome, while possibly mitigating the ramifications
for transcriptional silencing of UBE3A-AS.
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2. THE UBE3A ANTISENSE TRANSCRIPT UNDERGOES EXTENSIVE
PROCESSING AND IS SPATIOTEMPORALLY REGULATED IN THE BRAIN
2.1 Overview
Human chromosome 15q11-q13 contains a cluster of imprinted genes that are associ-
ated with a number of neurodevelopmental disorders that exhibit non-Mendelian patterns
of inheritance due to genomic imprinting, including Angelman syndrome (AS), Dup15q
syndrome, and Prader-Willi syndrome (PWS). AS is caused by loss of the maternally
inherited UBE3A allele, whereas PWS is caused by the loss of the paternally inherited
SNORD116 snoRNAs, which are expressed as part of a long polycistronic transcription
unit (PTU) comprised of SNRPN, additional snoRNA clusters, and the UBE3A antisense
transcript (UBE3A-AS). The PTU is imprinted with paternal-specific expression, and its
antisense portion exclusively expressed in neurons. As a result, UBE3A is imprinted in
neurons and biallelically expressed in all other cell-types. Why UBE3A-AS evolved to im-
printUBE3A in neurons is largely unknown. In this study, we examined the transcriptional
profiles and processing of the mouse and human antisense transcripts towards understand-
ing the functional significance of UBE3A imprinting by UBE3A-AS. Our findings show
that the UBE3A-AS is extensively processed via 5’ capping, 3’ polyadenylation, and alter-
native splicing, giving rise to a myriad of transcripts that are spatiotemporally regulated.
Based on our findings, we propose that processing of the UBE3A-AS generates a diverse
repertoire of regulatory RNAs in neurons.
2.2 Introduction
Human chromosome 15q11-q13 contains a cluster of genes that are associated with
a number of neurodevelopmental disorders exhibiting non-Mendelian patterns of inheri-
tance due to genomic imprinting. Angelman syndrome (AS) - characterized by intellectual
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disability, ataxia, epilepsy, and an atypical happy disposition - is caused by mutations or
epimutations leading to loss-of-function or loss-of-expression of the maternally inherited
ubiquitin protein ligase E3A (UBE3A) gene [34, 128, 129]. Maternal-derived interstitial
or isodicentric copy number gains of 15q11-q13 cause Dup15q syndrome, which is char-
acterized by intellectual disability, ataxia, epilepsy, sleep disorder, and autism spectrum
disorder [20, 130]. Although Dup15q is a contiguous gene disorder, overexpression of
UBE3A in the brain is believed to be the principal mechanism underlying the symptoms
associated with the condition [131]. Paternally inherited deletions of 15q11-q13, namely
those involving the C/D box small nucleolar RNA (snoRNA) SNORD116, cause Prader-
Willi syndrome (PWS), which is characterized by dysregulated hunger and satiety, ther-
moregulation, sleep disorder, and behavioral issues [132].
Genomic imprinting of the 15q11-q13 region is regulated by the AS and PWS im-
printing centers (AS-IC and PWS-IC) [11, 51, 118, 133, 134]. Studies to date indicate that
the AS-IC negatively regulates the PWS-IC [51], while the PWS-IC functions as an en-
hancer element that positively regulates the expression of genes in the region [46]. On
the maternal chromosome, the AS-IC is active and thus represses the expression of the
genes controlled by the PWS-IC. On the paternal chromosome, repressive histone mod-
ifications and DNA methylation inactivate the AS-IC allowing for the PWS-IC to reg-
ulate the expression of its target genes on the paternal chromosome, which including
the polycistronic transcriptional unit (PTU) comprised of SNURF/SNRPN, and clusters
of tandemly repeated C/D small nucleolar RNAs (SNORD107, SNORD64, SNORD108,
SNORD109A, SNORD116, and IPW). In the brain, transcription extends downstream of
IPW to include additional tandemly duplicated snoRNAs (SNORD115 and SNORD109B)
and the UBE3A antisense transcript (UBE3A-AS, also known as UBE3A-ATS). Likewise,
the mouse functional equivalent of the PWS-IC regulates the expression of a PTU com-
prised of Snurf/Snrpn, clusters of C/D box snoRNAs (Snord64, Snord116, Snord115,
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Ipw, and Ube3a-AS). But unlike in humans, expression of Snord116, Ipw, Snord115, and
Ube3a-AS is brain-specific [31, 135]. As such, the imprinting of UBE3A/Ube3a is brain-
specific, and aside from this role in imprinting there is no other function ascribed to it.
Studies in mouse and human have shown that expression of Ube3a-AS/UBE3A-AS
transcript is both necessary and sufficient to silence expression of the paternalUbe3a/UBE3A
allele in cis [36, 136]. But unlike most imprinted genes regulated by an antisense tran-
script, the Ube3a-AS/UBE3A-AS is believed to inhibit transcriptional elongation rather
than transcriptional initiation, as the paternal Ube3a allele is modified with active epige-
netic modifications, bound by RNA polymerase II, and transcribed to a region in intron
4 [36]. As such, Meng et al. (2013) proposed a collision model for the imprinting of
Ube3a in neurons, wherein Ube3a and Ube3a-AS expression decreases within intron 4
due to collision of the RNA polymerases. This model, however, conflicts with reports
detecting Ube3a-AS expression upstream Ube3a [122]. As such, this study sets out to
investigate the expression profile of Ube3a-AS/UBE3A-AS as a means to understand the
function of imprinting in neurons. Here, were report that Ube3a-AS/UBE3A-AS is a re-
markably complex transcript that is extensively processed through 5’ capping, alternative
splicing, and 3’ polyadenylation, which are differentially regulated among brain regions
and during brain development.
2.3 Materials & Methods
2.3.1 Bioinformatics
2.3.1.1 Public data, genomes and annotations
Publicly available data
The analysis performed in this chapter was conducted with publicly available data
downloaded from the European Nucleotide Archive, and can be viewed by the accession
number (http://www.ebi.ac.uk/ena/data/view/<accession>). Mouse tis-
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sue data was from 8 wk adults [137], while adult human data was of unknown age and ori-
gin for Human Protein Atlas (ERP003613) [138], and an average of 52.3 7.9 year-old for
the SRP072463 study [139]. The cellular populations in the mouse cerebral cortex dataset
were purified with various purification methods [140]. Temporal hippocampal RNA-seq
datasets were extracted from E18, P1, P10 and P30 mice [141]. A breakdown of tissue
types, strain, and accession numbers is supplied in APPENDIX B, Table B.1 for mouse
data and APPENDIX B, Table B.2 for human data. A complete list of publicly available
RNA-seq datasets used in this chapter is provided in Table 2.1.
Table 2.1: Public Data: RNA-seq information
Study Instrument Layout Stranded Species
ERP000591 Illumina Genome Analyzer PE No Mus musculus
SRP012040 Illumina HiSeq 2000 PE Yes Mus musculus
SRP033200 Illumina HiSeq 2000 PE No Mus musculus
SRP048593 Illumina HiSeq 2500 SE Yes Mus musculus
ERP003613 Illumina HiSeq 2000 PE No Homo sapiens
SRP072463 Illumina HiSeq 2000 PE Yes Homo sapeins
Genomes and annotation sets
Throughout this work, we used the February 2009, Genome Reference Consortium
Human Reference 37 (GRCh37, hg19) human genome assembly [142] and the July 2007
finished mouse genome NCBI Build 37 assembly [143] (mm9). Annotations were col-
lected from Illumina iGenomes collection for hg19 and mm9 last downloaded from UCSC
on July 17, 2015 [144].
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PolyA-seq data
PolyA-seq data files from Derti et al., 2012 [145] were downloaded from UCSC. The
sites clustered BED files from mouse and human (hg19) were separated by strand with
awk (version 4.0). These files were than viewed with IGV (version 2.3.90 [146,147]).
CAGE-seq data
CAGE (Capped Analysis of Gene Expression) sequencing bed files generated from the
FANTOM5 consortium [148] were downloaded from http://fantom.gsc.riken.
jp/5/datafiles/latest/extra/CAGE_peaks/. Similar to polyA-seq data, files
were separated by strand with awk and viewed in IGV.
2.3.1.2 Data processing
Quality of downloaded raw fastq files were checked with FastQC [149] (version 0.11.5).
As no read files failed initial quality control, adapter sequences and low quality reads (qual-
ity score 3) were trimmed with Trimmomatics [150] (version 0.36). Using the program’s
TruSeq3-PE-2.fa adapter file, and minimal length of 25. These trimmed paired- and single-
end reads were used by Hisat2 [151,152] (version 2.0.4) to align to chromosome 15 (chr15)
for human and chromosome 7 (chr7) for mouse data. The alignment was assisted with
Hisat2 python provide extraction scripts for splice sites and exons within chr15 and chr7,
human and mouse alignments respectively. The SAM file outputs were directly pipped
into SAMtools [153] (version 1.3.1) to convert to BAM format (samtools view) and
sorted (samtools sort) outputting only sorted BAM files to be indexed (samtools
index) and merged (samtools merged). The sorted BAM files were assembled with
StringTie [151, 154] (version 1.3.3). Annotation files using stranded, high-depth reads
(SRP01204, SRP072463) were generated via stringtie de novomethod for mouse and
human datasets. These GTF annotation files were merged with stringtie --merge
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using FPKM thresholds of 5 and 10 for mouse and human data respectively. Mouse data
was additionally restricted with isoform fraction equal to 0.05. These annotations were




All visualization was conducted with IGV. Novel transcript annotation (GTF) in the
antisense direction (minus - mouse, plus - human) were visualized along with polyA-seq
and CAGE-seq brain-specific annotations (BED). For UBE3A/Ube3a antisense specific
visualization, potential transcripts were extracted using a combination of awk and grep.
For splice junction visualization, sorted BAM files merged by tissue and study plotted
using the Sashimi plot function within IGV. Here, BAM files were limited to the antisense
direction of UBE3A/Ube3a.
Differential transcript expression
For differential expression on the transcript and exon level, the edgeR [157, 158] (ver-
sion 3.16.5) package download from Bioconductor [159, 160] (version 3.4, R [161] - ver-
sion 3.3.2) was used in conjunction with featureCounts. The featureCounts
produced read counts were used to generate an DGEList object for downstream anal-
ysis. The data was filtered based on counts per million (CPM) greater than 1 for 25%
of the samples. Data was than normalized by library size with calcNorm- Factors
an edgeR function and the negative binomial dispersion estimated by weighted likelihood
empirical Bayes [157, 162]. A negative binomial generalized log-linear model was fitted
to the data based on experimental design with glmFit [163]. Differential expression was
statistically tested on the isoform/transcript and exon levels using glmLRT [163] for One-
Way ANOVA-like statistics and exactTest [164] for pairwise comparisons of group
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means. The topTags function [164,165] was used to adjust p-values with the Benjamini
& Hochberg method (FDR) [166]. Finally, diffSpliceDGE was used to test for differ-
ential splicing and exon usage.
SNP analysis
As F1 hybrid mice (maternal, C57BL/6J and paternal, DBA/J2) RNA-seq data was
used, informative SNPs were extracted from the data using SAMtools samtools mpileup
and BCFtools (version 1.3.1) snp calling and conversion functions (bcftools call,
bcftools view) on sorted, indexed BAM files. A list of six SNPs from the region of
interest was downloaded from the Mouse Genomes Project - Query SNPs [167, 168] after
conversion of mm9 genomic coordinates to mm10 via LiftOver - an UCSC tool (http:
//genome.ucsc.edu/cgi-bin/hgLiftOver). The -r option for samtools




Mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed in
mouse facility under the specific-pathogen-free barrier conditions. All procedures were
performed according to NIH guidelines and approved by the Texas A&M University In-
stitutional Animal Care and Use Committee.
2.3.2.2 Rapid amplification of cDNA ends: 3’ polyA
3’ polyA rapid amplification of cDNA ends (3’ RACE; 18373019, Life Technolo-
gies, Carlsbad, CA) was performed according to the manufacture’s protocol using total
RNA isolated from cortex and cerebellum of adult (10 wk) male C57BL/6J mice (000664,
The Jackson Laboratory) and FirstChoice Human Brain Reference Total RNA (6050,
27
Life Technologies). Briefly, mouse RNA was isolated using TRIzol reagent (15596018,
Thermo Fisher Scientific, Waltham, MA) according to the manufacturers protocol and
then DNase treated using TURBO DNA-free kit (AM1907, Life Technologies). 3’ RACE
primers were designed using an annotation of Ube3a-AS/UBE3A-AS (personally commu-
nication). The primers were directed towards the 3’ ends of Ube3a-AS/UBE3A-AS and up-
stream of the polyadenylated sites predicted by Derti et al. [145] (APPENDIX B, Tables
B.3 and B.4). 3’ RACE was performed using the AUAP universal primer and primers spe-
cific to the 3’ ends of Ube3a-AS/UBE3A-AS. PCR amplicons were gel extracted (D4008,
Zymo Research, Irvine, CA) and cloned into the PCR4-TOPO TA vector (K458001, Life
Technologies). Vectors containing PCR inserts were identified by restriction digests of
the plasmids (EcoRI-HF, R3101M, New England BioLabs Inc., Ipswich, MA). Sanger se-
quencing of the RT-PCR amplicons was performed at the Texas A&M University Gene
Technologies Laboratory (http://www.idmb.tamu.edu/gtl/). Sequences were
visualized in IGV (BLAT) and exported as BED files to be binded together with paste
(Bash), sorted with sortBed and merged with bedtools merge - BEDtools [169]
(version v2.25.0) utilities. The merged BED files were visualized with polyA- and CAGE-
seq data in IGV.
2.3.2.3 Quantitative RT-PCR
Quantitative RT-PCR (qPCR) was used to examine differential expression of Ube3a-
AS in cortex, cerebellum, and hippocampus of adult (10 wk) male mice (C57BL/6J, n = 4).
Tissues were dissected and flash frozen with liquid nitrogen, and then RNA was isolated
and processed as described above. Reverse transcription was performed using the Super-
Script IV First Strand Synthesis System (Life Technologies) with oligo(dT) primer. The
qPCR assays were performed in triplicate using SYBR-Green reagent (11760500, Life
Technologies) on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
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City, CA). A list of primers is provided in APPENDIX B, Table B.4. Statistical signifi-
cance was determined for the qPCR using two-way ANOVA in R (aov) and Tukey’s HSD
multiple comparison post-hoc analysis was performed (TukeyHSD) with default parame-
ters.
2.3.3 Charts
All charts were generated in R using the ggplot2 library and the pdf function -
devtools library.
2.4 Results
2.4.1 The antisense transcript of UBE3A/Ube3a is a highly processed transcript produc-
ing multiple isoforms
The genome annotation for mouse was generated using high read depth, stranded data,
merged from cortex, cerebellum, and frontal lobe (C57BL/6J, n = 2). Similar, the human
genome annotation was generated using high read depth, stranded data from merged Brod-
mann area 4 (motor cortex, n = 4). In both cases, several transcripts were assembled in
the antisense direction of UBE3A/Ube3a (mouse = 18, human = 10) that overlapped the
sense UBE3A/Ube3a (Figure 2.1). In the case of the mouse, several transcripts terminated
upstream Ube3a (Figure 2.1A). Furthermore, both annotations revealed transcriptional
interconnection between the upstream SNORD115/Snord115 cluster1.
To investigate processing of the antisense transcripts, we applied publicly available
polyA-seq and CAGE-seq in conjunction with 3’ RACE (Figure 2.2). In the antisense
direction of UBE3A/Ube3a, polyadenylation sites were identified with several verified by
3’ RACE sequence data (APPENDIX B). Analysis of antisense direction CAGE data
revealed 5’ capped sites within the antisense region. Combined with the polyadenylation
data, this suggested that the antisense transcripts are being processed into smaller RNAs.


















































































































As the UBE3A/Ube3a region is imprinted, it was important that we identify allelic
origin of expression. To this end, the hybrid mice - sequenced by Sanger Institute Col-
laboration - were used to identify informative SNPs in the region. Of the six SNPs in the
region, five of them had approximately 97.8% expression from the paternal (DBA) allele
at 52.1% coming from the reverse strand (APPENDIX B, Table B.5). Suggesting that
these antisense transcripts are being expressed from the paternal allele.
In addition to the 3’ and 5’ processing of these antisense transcripts, we observed
numerous splicing and alternative splicing in the antisense direction with Sashimi plots
within the mouse cortex (Figure 2.3A), and within the human Brodmann area 4 (Figure
2.3B).
We used publicly available RNA-seq [137, 139], polyA-seq [145], CAGE-seq [148]
data to characterize the expression patterns, splicing, 3’ polyadenylation, and 5’ cap-
ping of the antisense transcript of UBE3A/Ube3a in mouse and human. Altogether, these
data indicate that the antisense transcripts for mouse and human are processed into multi-
ple transcriptional units through alternative splicing, 5’ capping, and 3’ polyadenylation.
The presence of 5’ capped transcripts at exonic and intronic regions also suggests post-
transcriptional processing.
2.4.2 The UBE3A-AS/Ube3a-AS is brain-specific and highly expressed in neurons
We next examined the expression profile and patterns of the antisense transcript among
mouse and human tissues and among individual populations of mouse cerebral cortex cell-
types using RNA-seq data [138,140]. Alternative splicing in the antisense direction nearly
disappeared completely in non-brain tissues in both mouse (APPENDIX B, Figure B.1)
and human (APPENDIX B, Figure B.2). Analysis of isoform expression revealed that
all of the antisense transcripts were downregulated in heart, liver and lung compared to











































































































































































































































































































Figure B.3D-F). Similar, Ube3a-AS transcripts were all downregulated in astrocytes, OPC
(oligodendrocytes precursor cells), NFO (newly formed oligodendrocytes), MO (myelinat-
ing oligodendrocytes), microglia, and endothelial cells compared to neurons (APPENDIX
B, Figure B.4, and B.5).
As coverage was low for the tissue RNA-seq data, we looked at exon usage between
tissues and cell-types of cerebral cortex to determine significant changes in expression.
Three general isoform categories were determined for mouseUbe3a-AS based on 3’RACE
polyadenylation sites, and one for human UBE3A-AS based on 3’RACE polyadenylation
(Figure 2.4A). Using this method, expression were significantly downregulated compared
to the hippocampus in mouse (p-value< 0.001, FDR< 0.001; Figure 2.4B), and cortex in
human (p-value< 0.001, FDR< 0.001; Figure 2.4C) with log2 fold-changes all below -2.
Similarly, cell-type expression was also significantly downregulated compared to neurons
in mouse (p-value< 0.001, FDR< 0.001; Figure 2.4D). Exon genomic position are listed
in APPENDIX B, Table B.6.
Altogether, these data demonstrates that the antisense transcript of Ube3a/UBE3A is
brain-specific, and that Ube3a-AS is also highly expressed in neurons compared to other
cell-types in cerebral cortex.
2.4.3 The Ube3a-AS is spatiotemporally regulated
We next asked whether the antisense transcripts are differentially regulated among
brain regions. Using the same general isoforms categories above (Figure 2.4A), we looked
at the fold-change comparing cortex to cerebellum and frontal lobe, and frontal lobe com-
pared to cerebellum (Figure 2.5A). Ube3a-AS isoform 1 (AS Iso1) and Ube3a-AS iso-
form 2 (AS Iso2) were significantly downregulated in cerebellum compared to cortex and
frontal lobe (p-value < 0.001, FDR < 0.001), while Ube3a-AS isoform 3 (AS Iso3) was
significantly upregulated in cerebellum compared to cortex and frontal lobe (p-value <
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Figure 2.4: Ube3a-AS/UBE3A-AS demonstrates brain-specific differential expression and
is upregulated in neurons. A. Schematic of the exons used for differential exon usage
comparison. 3’RACE locations marked below annotations. B. Differential expression
of Ube3a-AS isoforms comparing hippocampus to heart, liver, and lung. Data generated
from Sanger Institute hydrid mice data. C. Differential expression of UBE3A-AS isoform
comparing cortex to heart, liver, and lung. Data generated from Uhlen et al. (2015).
D. The three mouse isoforms are downregulated in non-neuronal cell-types compared to
neurons. Data generated from Zhang et al. (2014). P-value and FDR plotted in B-C. ***
denotes p-value < 0.001. Abbreviations: OPC - oligodendrocytes precursor cells, NFO -
newly formed oligodendrocytes, and MO - myelinating oligodendrocytes.
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0.001, FDR < 0.001). There appeared to be no difference between cortex and frontal lobe
expression, which is unsurprising given their locations in the brain.
To expand upon our findings that Ube3a-AS is differentially expressed among mouse
brain regions, we used quantitative RT-PCR to examine the levels of the three general
isoforms among adult mouse cerebellum, cortex, and hippocampus (C57BL/6, n=3; Fig-
ure 2.5B). The levels of each transcript were significantly different among the brain re-
gions (ANOVA, F < 0.001), with significantly higher levels of relative expression for AS
Iso1 in cortex and hippocampus compared to cerebellum (Tukey’s HSD, p.adj < 0.01;
p.adj < 0.01). AS Iso3 had significantly higher levels of relative expression in cerebellum
compared to cortex or hippocampus (Tukey’s HSD, p.adj < 0.001), which supported the
RNA-seq analysis. AS Iso2 was virtually undetectable in all brain regions.
In addition to spatial analysis, we also wanted to see if Ube3a-AS was regulated during
brain development in the hippocampus (Figure 2.5C). Using the general isoforms, we
examined the fold-change comparing E18 to P1, P10, and P30 finding that AS Iso2 was
significantly upregulated in P30 compared to E18 (p-value < 0.01, FDR < 0.05). When
comparing P1 to P10 and P30, we found that expression of AS Iso1 was significantly
upregulated compared to P10 and P30 (p-value < 0.01, FDR < 0.05), and AS Iso2 was
significantly upregulated compared to P30 (p-value < 0.001, FDR < 0.001). AS Iso3 did
not appear to be significantly upregulated.
Altogether, these findings indicate that Ube3a-AS is differentially regulated among
brain regions and during brain development.
2.5 Discussion
In this study, we investigated expression profiles of the antisense transcript toUbe3a/UBE3A,
and determined that the Ube3a/UBE3A antisense transcript is extensively processed in the
brain with 5’ capping, 3’ polyadenylation, and alternative splicing. In addition to this,
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Figure 2.5: Ube3a-AS is spatiotemporally regulated in the brain. A. Log2 fold-change
comparing cortex, cerebellum and frontal lobe (n = 2). Data generated from Pervouchine
et al. (2015). B. qPCR relative expression comparing isoform expression between cortex,
cerebellum and hippocampus (n = 3). C. Log2 fold-change comparing developmental
timepoints (E18, P1, P10, and P30) within the hippocampus (n = 2). Data generated from
You et al. (2015). P-value and FDR ploted in A. and C. *** denotes p-value < 0.001, **
denotes p-value < 0.01, and * denotes p-value < 0.05.
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we demonstrated that Ube3a-AS/UBE3A-AS is brain-specific, and in mice, upregulated in
neurons with paternal exclusive expression. Lastly, we found that Ube3a-AS is spatiotem-
porally expressed. Based on these findings, we propose that Ube3a-AS/UBE3A-AS is a
highly processed transcript with potential functionality.
Studies to date indicate that theUBE3A-AS is transcribed as part of a long polycistronic
transcriptional unit on the paternal chromosome [31, 37, 118]. Our results are consistent
with this theory (APPENDIX B, Figure B.6); furthermore, we found that several of tran-
scripts assembled were highly interconnected with the upstream Snord115/SNORD115
gene. Additionally, we did not observe any 5’ capping near the predicted 5’ ends of the
mouse antisense transcripts. The presence of 5’ capped transcripts in Ube3a-AS/UBE3A-
AS region lacked an active transcriptional start site and aligned either to exonic or intronic
regions suggesting post-transcriptional modifications [170–172]. Furthermore, we iden-
tified and verified polyadenylation sites throughout both intronic and exonic regions of
Ube3a-AS/UBE3A-AS. Altogether suggesting that the region is transcribed as 5’ capping
and 3’ polyadenylation are often coupled with transcription to prevent degradation of the
RNA transcript, facilitate nuclear export, and/or promote translation [173].
We also confirm that the Ube3a-AS/UBE3A-AS is primarily, if not exclusively, ex-
pressed in the brain. Splicing in the antisense direction was almost completely eliminated
in non-brain tissues. Furthermore, upon examination of differential expression in cere-
bral cortex cell populations, we observed a drastic decrease in splicing in non-neuronal
cell-types that are consistent with previous studies that imprinting of Ube3a is neuron-
specific [34, 128]. By using exon level differential expression, we were able to see log2
fold-changes greater than 2, which was not apparent with transcript level differential ex-
pression. This could be due to the overlapping regions of Ube3a/UBE3A and the anti-
sense transcripts. As such, general antisense isoforms were chosen near the 3’ ends of the
antisense transcript where 3’RACE had confirmed the polyadenylation site. Interestingly,
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these isoforms appeared to also be differentially expressed within tissue and cell-type com-
parisons with isoform 1 having the, overall, highest differential expression.
In addition to being differentially expressed, we determined that the Ube3a-AS iso-
forms were also spatially regulated within the brain with isoform 3 upregulated in cerebel-
lum, and isoform 1 and 2 upregulated in cortex, frontal lobe, and hippocampus. Further-
more, we determined that Ube3a-AS was also temporally regulated in the hippocampus
with expression of isoform 1 during the P1 developmental time period. This was of inter-
est as Creb3l1 - a cAMP protein; Kcnd2 - a potassium voltage-gated channel protein; Stx3
- a syntaxin protein; and Slc6a4 - a neurotransmitter protein are also temporally regulated
in the brain at the P1 stage [174, 175]. Isoform 2 expressing during the P10 time period,
where several enhancers and transcription factors like Hes3 and Atf6 are also temporally
regulated in the brain [174, 175]. We did not observe temporal regulation with isoform 3;
however, as the tissue examined was hippocampal and isoform 3 showed significant up-
regulation in cerebellum tissue. As such, it is possible that isoform 3 could be temporally
regulated in cerebellum.
Altogether, these findings provide insight into the function of the UBE3A-AS and the
function of neuron-specific imprinting of UBE3A. Processing of mRNA and ncRNA to
generate shorter RNA transcripts often expand the functional capacity of the transcrip-
tome, generating shorter RNAs and in some instances isoforms with coding potential.
Here, we propose that UBE3A-AS is expressed in neurons for a regulatory function out-
side of the imprinting of UBE3A. Furthermore, these new insights offer clues as to how
the antisense can be targeted for therapeutic intervention and raises potential ramifications
of doing so.
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3. ANTISENSE MEDIATED ALTERNATIVE SPLICING REGULATES
IMPRINTING OF Ube3a IN NEURONS
3.1 Overview
Loss of the maternally inheritedUBE3A allele causes Angelman syndrome, a debilitat-
ing neurological disorder associated with intellectual disability, absent speech, and ataxia.
In both mouse and human, the UBE3A gene is imprinted with maternal-allelic expres-
sion in neurons of the CNS through the expression of the UBE3A antisense transcript
(UBE3A-AS), which is both necessary and sufficient for establishing the imprint. Unlike
most imprinted genes though, UBE3A-AS inhibits transcriptional elongation - rather than
transcriptional initiation - of the paternal UBE3A allele. The mechanism by which this oc-
curs is unknown. Here we show that mouse Ube3a-AS imprints Ube3a through alternative
splicing and the use of an intronic alternative polyadenylation site. These findings provide
insight into the functional significance of imprinting of UBE3A in neurons and also reveal
novel strategies to reactivate expression of the paternal UBE3A as a therapy for individuals
with Angelman syndrome.
3.2 Introduction
Human chromosome 15q11-q13 contains a cluster of imprinted genes that are associ-
ated with number of neurogenetic syndromes. Maternal derived mutations or epimutations
leading to the loss of ubiquitin protein ligase E3A (UBE3A) gene cause Angelman syn-
drome, which is associated with intellectual disability, ataxia, epilepsy, and an atypical
happy disposition [2, 3]. UBE3A is a member of the ubiquitin proteasome system, where
it covalently attaches ubiquitin polypeptides to target proteins [176]; it also functions as
a co-activator of nuclear steroid hormone receptors [177, 178]. The specific targets and
pathways underlying the symptoms associated with AS, however, remain unclear. Paternal
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derived mutations or epimutations leading to the loss of the C/D box SNORD116 snoR-
NAs (small nucleolar RNAs) cause Prader-Willi syndrome (PWS), which is characterized
by dysregulated hunger and satiety, thermoregulation, sleep-disorder, and behavioral is-
sues [132]. Currently, the function of the SNORD116 snoRNAs in the brain is poorly
understood.
The UBE3A gene is located at the telomeric end of the 15q11-q13 imprinted region
and is orientated in the opposite direction of the C/D box snoRNA clusters (SNORD115
and SNORD116) and the SNURF-SNRPN gene. The SNURF-SNRPN gene and snoRNA
clusters are expressed from the paternal allele as a long polycistronic transcriptional unit
(PTU) that is also transcribed in the antisense direction across UBE3A - the 3’ end of the
PTU is hence referred to as the UBE3A antisense (UBE3A-AS, also known as UBE3A-
ATS) transcript [37]. Recent studies have demonstrated that transcription of UBE3A-AS
is both necessary and sufficient to silence expression of the UBE3A sense transcript in
mice [36, 136]. Moreover, since the PTU is transcribed exclusively from the paternal
allele and expressed only in neurons, UBE3A is imprinted with maternal-allelic expression
in neurons and biallelically expressed in all other cell types [34, 37]. An orthologous
region exists on mouse chromosome 7C where imprinting of Ube3a and the PTU is also
conserved, which makes the mouse an excellent model for investigating the imprinting of
Ube3a.
Currently, the mechanism by which Ube3a-AS inhibits expression of Ube3a is unclear.
Whereas most antisense transcripts regulate expression of their sense counterparts by in-
hibiting transcriptional initiation [85,99,179], Ube3a-AS appears to inhibit transcriptional
elongation of Ube3a. Meng et al. [36] reported that the paternal Ube3a allele is modified
with active histone modifications, bound by RNA polymerase II, and transcribed up to a re-
gion in intron 4, where bothUbe3a sense and antisense transcript levels diminish [35,122].
Based on these observations, Meng et al. [36] proposed a transcriptional collision model of
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genomic imprinting in which the Ube3a and Ube3a-AS transcriptional complexes collide,
causing each to stall and dissociate from their respective template strands [36].
Recently, our laboratory detected high levels of Ube3a-AS transcripts as far as 40 kb
upstream of Ube3a (Chapter 2), which is at odds with the transcriptional collision model.
Based on this observation, we explored alternative mechanisms by which the antisense
could inhibit transcriptional elongation of the paternalUbe3a allele. Here, we demonstrate
the existence of a paternally expressed, short Ube3a isoform (isoform 4) that undergoes
early termination through the use of an intronic alternative polyadenylation site in intron
4. Isoform 4 is polyadenylated and expressed exclusively in the brain from the paternal
allele. Pharmacological inhibition of Ube3a-AS in mouse primary hippocampal neurons
ablates the use of the intronic alternative polyadenylation site, resulting in reactivation of
the paternal Ube3a allele. Based on these findings, we propose that Ube3a-AS regulates
imprinting of Ube3a through alternative splicing and intronic alternative polyadenylation.
3.3 Materials & Methods
3.3.1 Bioinformatics
3.3.1.1 Public data, genomes and annotations
Publicly available data
The bioinformatic analysis performed in this chapter was conducted using publicly
available data downloaded from the European Nucleotide Archive. Mouse tissue data was
from 8 wk adults [137]. Topotecan treated neuron data were cultured cortical neurons (10
days in vitro) with a 72 h treatment on day 7 [53]. Finally, mouse cerebral cortex cellular
populations data were purified using various methods specific to the cell-type [140]. A
breakdown of tissue types, strain, and accession is supplied in APPENDIX C, Table C.3.
A complete list of publicly available RNA-seq datasets used in this chapter is provided in
Table 3.1.
42
Table 3.1: Public Data: RNA-seq information for Ube3a mechanism
Study Instrument Layout Stranded Strain
ERP000591 Illumina Genome Analyzer PE No C57BL/6J x DBA/2J
SRP012040 Illumina HiSeq 2000 PE Yes C57BL/6J
SRP017966 Illumina HiSeq 2000 PE/SE No C57BL/6J x CASTEi/J
SRP033200 Illumina HiSeq 2000 PE No Multiple
Genomes and annotation sets
Throughout this work, the July 2007 finished NCBI Build 37 mouse genome assembly
[143] (mm9) was used. Annotations were collected from Illumina iGenomes collection,
using the July 17, 2015 UCSC annotations [144].
PolyA-seq and CAGE-seq data
PolyA-seq BED files [145] were downloaded from UCSC, while CAGE-seq BED files
[148] were downloaded from http://fantom.gsc.riken.jp/5/datafiles/
latest/extra/CAGE_peaks/. The polyA sites clustered datasets and CAGE-seq
peak files was separated with awk (Bash version 4.0) and viewed with IGV (version 2.3.90
[146,147]).
3.3.1.2 Data processing
The quality of the fastq files were checked with FastQC [149] (version 0.11.5), fol-
lowed by adapter and low quality (quality score  3) sequence trimming with Trimmo-
matics [150] (version 0.36). The TruSeq3-PE-2.fa adapter file from Trimmomatics adapter
file was used for adapter cutting and a minimal length of 25 was set. Paired- and single-end
trimmed reads were than aligned with Hisat2 [151, 152] (version 2.0.4) to chromosome 7
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(chr7) with the assistance of Hisat2 provided python scripts that extracted splice sites and
exons from chr7. The SAM file were directly pipped into SAMtools [153] (version 1.3.1)
to convert to BAM format (samtools view) and sorted (samtools sort). These
files were merged (samtools merge) and indexed (samtools index) by biologi-
cal replicas for viewing in IGV. StringTie [151, 154] (version 1.3.3) was used to assemble
the sorted BAM files (unmerged). Individual annotation files for stranded, high-depth
reads (SRP01204) was generated via stringtie using the de novomethod, and merged
(stringtie --merge) using FPKM threshold of 5, and isoform fraction of 0.05. This
merged annotation file was used as a reference for the Rsubread [156] (version 1.24.1)
function featureCounts [155] for downstream analysis.
3.3.1.3 Data analysis
Visual analysis
All visualization was conducted with IGV. Novel transcript annotation (GTF) on the
forward strand were visualized along with polyA-seq and CAGE-seq brain-specific anno-
tations (BED). For Ube3a specific visualization, potential transcripts were extracted using
a combination of awk and grep. Sashimi plots - a utility within IGV - were used to
visualize alternative splicing limited to the forward strand.
Differential expression analysis with edgeR
The Bioconductor [159, 160] (version 3.4, R [161] version 3.3.2) package, edgeR
[157,158] (version 3.16.5), was used to determine differential expression on the transcript
and exon level. Read counts were generated with featureCounts, which was used
to generate an edgeR DGEList object from count, group, and annotation information.
Data was filtered (CPM 1, for 25% of samples) and normalized (calcNormFactors)
before the dispersion was estimated [157, 162] and fitted to a negative binomial gen-
eralized log-linear model [163]. Isoform/transcript and exon levels differential expres-
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sion was statistically tested with exactTest [164] for pairwise comparisons of group
means and p-values were adjusted using Benjamini & Hochberg method (FDR) [166] with
topTags [164, 165].
SNP analysis
Informative SNPs were extracted from hybrid mice (maternal, C57BL/6J and paternal,
DBA/J2) via samtools mpileup and BCFtools (version 1.3.1) bcftools call
and bcftools view on sorted, indexed, merged BAM files. A list of SNPs in the
region was downloaded from the Mouse Genomes Project - Query SNPs [167, 168] and
coordinates were converted from mm10 to mm9 using LiftOver - an UCSC tool (http:
//genome.ucsc.edu/cgi-bin/hgLiftOver). Region of interest, specified with
the -r option for samtools mpileup, was chr7:66,439,800-66,808,000.
3.3.2 Molecular
3.3.2.1 Animals
Animals were housed under standard conditions in a pathogen-free mouse facility.
All procedures performed according to NIH guidelines and approved by the Texas A&M
University Institutional Animal Care and Use Committee (IACUC). The laboratory of Dr.
Arthur Beaudet generated and providedUbe3aY FP mouse model [128]. B6D2F1 (100006)
hybrid mice were obtained from the Jackson Laboratory (Bar Harbor, ME). TheUbe3aY FP
mice were maintained on C57BL/6J background (000664, The Jackson Laboratory).
3.3.2.2 Primary neuronal culture
This study involved the establishment of primary hippocampal neurons from the off-
spring of female wild-type, C57BL/6J, and male Ube3a+=Y FP mice as previously de-
scribed [180] with slight modifications. Briefly, hippocampi were dissected from P0-P2
mice and held on ice in hibernate medium (A1247501, Life Technologies, Carlsbad, CA)
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supplemented with 2% B27 (17504044, Life Technologies) during surgery. Neurons were
dissociated by trypsin treatment (10 min at 37C and 600 rpm) using TrypLE (12604021,
Life Technologies) and triturated with a glass Pasteur pipette in Neuron culture media
consisting of Neuralbasal Media (21103049, Life Technologies) supplemented with 1%
GlutaMAX (35050061, Life Technologies), 1% penicillin/streptomycin (15140122, Life
Technologies), and 2% B27. Neurons were plated on 6-well cell culture plates coated
with poly-l-ornithine (P0421, Sigma-Aldrich, St. Louis, MO) and laminin (23017015,
Life Technologies). Typical plating density was one animal per well in a 6-well plate with
cultures maintained at 37C (95% O2, 5% CO2).
3.3.2.3 3’ Rapid amplification of cDNA ends analysis
Total RNA was isolated from flash frozen cortex of adult 10-week old male C57BL/6J
mice using TRIzol (15596018, Life Technologies) following the manufacturer’s protocol.
Gene specific primers (APPENDIX C, Table C.2) were designed to perform 3’ RACE us-
ing AUAP universal primer (18373019, Life Technologies) following the manufacturer’s
protocol. PCR amplicons were cloned using the TOPO TA cloning kit (K458001, Life
Technologies) and sequenced at the Texas A&M University Gene Technologies Labora-
tory. Sequences were visualized with IGV using the BLAT function and BED files were
exported, binded together (paste, Bash), sorted (sortBed) and merged (bedtools
merge) with BEDtools [169] (version v2.25.0). The merged BED files were visualized
together with polyA- and CAGE-seq data in IGV.
Gene structure analysis
Gene structure prediction was performed using the GeneSeqer program [181]. Briefly,
the genome annotation was converted to a FASTA file using gffread -w (http:
//ccb.jhu.edu/software/stringtie/gff.shtml#gffread). The Ube3a
protein ESTs (expressed sequence tags) were downloaded from NCBI as FASTA files.
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Using the GeneSeqer command for mouse, the forward strand was analyzed with the
protein EST library for the predicted Ube3a isoform 4.
3.3.2.4 Cell culture treatment with Topotecan
Total RNA was isolated from Ube3a+=Y FP cultured primary neurons using a PureLink
kit (12183018A, Life Technologies). Topotecan hydrochloride (1672257, Sigma-Aldrich)
was added to 3 ml total of Neuron culture media in 6-well plate (72 h treatment) at a final
concentration of 300 nM in 1X TE buffer (12090015, Life Technologies).
3.3.2.5 Reverse-transcription and quantitative PCR analysis
Four month old B6D2F1 female mice were dissected and the lung, liver, kidneys, heart,
ovaries, and cortex were flash frozen. RNA was isolated using TRIzol and treated with
TURBO DNA-free kit (AM1907, Life Technologies). Complementary DNA was gener-
ated using SuperScript IV (18091050, Life Technologies) with oligo(dT) primers. RT-
PCR was preformed on adult mouse tissues with forward primer for exon 4 and reverse
primers for exon 4.1 and 5. SYBR-Green (11760500, Life Technologies) was used to
assay mRNA expression level using the 7900HT Fast Real-Time PCR System (4351405,
Applied Biosystems, Foster City, CA). Expression data were normalized using ActB and
neuron expression was normalized using Map2. All primers listed in APPENDIX C, Ta-
ble C.2. Statistical significance for qPCR expression data was determined using two-way
ANOVA calculated in R (aov). Post-hoc analysis was performed simultaneously using
Tukey’s HSD multiple comparison (TukeyHSD) with default parameters.
3.3.3 Charts
Charts generated in R using ggplot2 and pdf, a devtools function.
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3.4 Results
3.4.1 Novel Ube3a isoform 4 expressed exclusively from the brain
While investigating the alternative splicing patterns of Ube3a in publicly available
RNA-sequencing (RNA-seq) data sets, we identified a novel Ube3a isoform involving
splicing between exon 4 and an unannotated exon (hereafter referred to as exon 4.1) in
intron 4 (Figure 3.1A). The novel splice site was detected exclusively in transcriptome
assemblies of mouse brain and not in any other organ or tissue (APPENDIX C, Figure
C.1) and downregulated in other tissues (APPENDIX C, Figure C.2). Moreover, alter-
native splicing into exon 4.1 was only detected in neurons (APPENDIX C, Figure C.3)
and the isoform downregulated in other cell-types (APPENDIX C, Figure C.4). 3’RACE
and Sanger sequencing demonstrated that exon 4.1 was a terminal exon, aligning with
the polyA-seq polyadenylation signal (Figure 3.1B), and revealing an in-frame coding se-
quence preceding a stop codon (Figure 3.1C). RT-PCR analysis (polyA enriched RNA)
showed that Ube3a isoform 4 was expressed in adult mouse cortex but not heart, liver, kid-
ney, and ovary (Figure 3.1D), confirming our RNA-seq analysis. Altogether, these data
demonstrate the expression of a novelUbe3a isoform expressed in brain, hereafter referred
to as Ube3a isoform 4.
3.4.2 Ube3a isoform 4 is paternally expressed
We next investigated the mRNA (polyA enriched) transcriptomes of adult hybrid (C57BL/6J
x DBA/2J) mice hippocampus (n = 6) produced by the Sanger Institute to determine the
allelic expression of Ube3a isoform 4. Analysis of informative single nucleotide variants
(sense expressed transcripts) showed that Ube3a isoform 4 was primarily expressed from




































































































































































































































































































Table 3.2: SNP frequency for C57xDBA hybrid mice - exon 4.1 region
SNP Location Ref Alt Allelic Freq
T/G Chr7:66507227 0 7 -1.00
C/T Chr7:66508429 1 13 -0.93
C/A Chr7:66508469 1 30 -0.96
G/A Chr7:66509079 0 13 -1.00
A/T Chr7:66509131 0 17 -1.00
3.4.3 Ube3a-AS regulates the expression of Ube3a isoform 4
Our findings prompted us to hypothesize that the antisense transcript of Ube3a reg-
ulated alternative splicing of Ube3a isoform 4. To test this, we first analyzed RNA-seq
data generated by King et al., (2013), which consists of transcriptomes of mouse primary
neurons treated either with a vehicle (DMSO) or Topotecan, a topoisomerase inhibitor
that reactivates expression of the paternal Ube3a allele by inhibiting expression of the
Ube3a-AS transcript [52, 53]. Analysis of the transcriptomes revealed splicing into exon
4.1 in the control neurons but not the Topotecan treated neurons (Figure 3.2A). Analy-
sis of isoform expression demonstrated significant downregulation of Ube3a isoform 4 in
Topotecan treated neurons; however, there did not appear to be a significant fold-change
in expression of the other three isoforms (Figure 3.2B).
An investigation into exon usage of Ube3a showed similar expression levels of Ube3a
exon 4 in the control and Topotecan treated neurons; however, expression of exons 5 was
significantly upregulated in the Topotecan treated neurons (Figure 3.2C), while it was sig-
nificantly downregulated in exon 4.1. We then treated primary hippocampal neurons with
Topotecan and vehicle (1X TE buffer) and used qPCR to quantify expression of Ube3a
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isoform 4. Consistent with the RNA-seq analysis, the Topotecan treated neurons had sig-
nificantly reduced relative expression levels of Ube3a-AS (TukeyHSD, p-value < 0.0001)
and Ube3a isoform 4 (TukeyHSD, p-value < 0.001) compared to controls (Figure 3.2D).
Taken together these findings demonstrate that Ube3a-AS regulates alternative splicing of
Ube3a paternal sense expression.
3.5 Discussion
Here we demonstrate the existence of a brain-specific, paternally expressed Ube3a
isoform that terminates in intron 4 and that is dependent on expression of the Ube3a-AS
transcript. Based on these findings, we propose that Ube3a-AS inhibits transcriptional
elongation of the paternal Ube3a allele through alternative splicing and the use of an in-
tronic alternative polyadenylation signal. This notion is consistent with numerous reports,
including imprinted genes, describing the antisense regulation of sense alternative splic-
ing [182, 183]. Whether transcription of Ube3a-AS affects the elongation kinetics of the
paternal Ube3a transcriptional complex, leading to inclusion of the exon 4.1, or whether
the Ube3a-AS transcript induces inclusion of exon 4.1 by masking the downstream splice
acceptor sites or regulatory elements is unknown and warrants further investigation.
We investigated the link between Ube3a-AS and Ube3a isoform 4 with Topotecan, a
drug known to effect alternative splicing [184, 185]; and thus, this study does not clarify
whether the reduction in Ube3a isoform 4 expression is due primarily to the decrease in
Ube3a-AS expression or due to Topotecan. An alternative method to inhibition Ube3a-
AS specifically with either antisense oligonucleotides, similar to Meng et al. (2013), or
by using a PWS-IC paternal deletion transgenetic mouse model would answer this ques-
tion. Nevertheless, we provide for the first time evidence linking Ube3a-AS expression to
alternative splicing of the paternal Ube3a sense transcript.


































































































































































































































































































































tional significance of UBE3A imprinting in neurons. First, isoform 4 may have a neuron-
specific regulatory role. In this model, the expression of the antisense transcript expands
the functionality of Ube3a specifically in neurons. This theory is further supported by
our results showing temporal regulation of isoform 4 in hippocampal tissue (APPENDIX
C, Figure C.6). Conversely, the antisense transcript may have neuron-specific regulatory
functions. Given the recent studies in our laboratory demonstrating a remarkable com-
plexity to Ube3a-AS/UBE3A-AS expression patterns, with more than a dozen alternatively
spliced transcripts in mouse and at least ten alternatively spliced transcripts in human,
suggests a regulatory role for Ube3a-AS/UBE3A-AS in the brain (Chapter 2). Although
the functionality of these transcripts has yet to be investigation, their existence suggests a
model in which reciprocal imprinting allows for the expression of both sense and antisense
transcripts (i.e., the complementation model) [186, 187]. Finally, it is possible that both
isoform 4 and the antisense transcripts have a regulatory role within the brain; and thus,
increase the overall complexity of the treanscriptome in neurons.
In addition to proposing a new model for the imprinting of Ube3a in neurons, these
results also apply to the current therapeutic strategies for Angelman syndrome - reacti-
vation of the paternal UBE3A allele. Numerous laboratories, including ours, are actively
pursuing strategies to reactive expression of the paternal Ube3a/UBE3A allele. The feasi-
bility of this approach has been demonstrated using both pharmacological and epigenetic
methodologies [52, 123, 125]. More importantly, reactivation of the paternal Ube3a allele
has been shown to mitigate some of the phenotypes associated with the loss of Ube3a in
an Angelman syndrome mouse model [125, 126]. The link between isoform 4 and reacti-
vation of the paternal Ube3a allele offers a new target for AS therapeutics. Furthermore, it
highlights potential ramifications for the knockdown of Ube3a isoform 4 and Ube3a-AS.
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4. MOUSE EMBRYONIC STEM CELL-DERIVED NEURON HIGH-
THROUGHPUT DRUG SCREEN ASSAY FOR ANGELMAN SYNDROME
4.1 Overview
High-throughput drug discovery efforts for neurological disorders often rely on the use
of mouse primary neuronal cultures; however, establishing primary cultures from the ro-
dent brain is labor intensive, expensive and provides only a limited supply of cells. Mouse
embryonic stem cell-derived neurons are an ideal alternative to primary cultures, because
large quantities of cells are easily generated and readily differentiated into neurons in vitro,
providing an almost unlimited source of cells for high-throughput screening (HTS) assays.
Here, we developed and validated an ES cell-based HTS method to identify new therapies
for Angelman syndrome (AS), a severe neurodevelopmental disorder that is caused by loss
of the maternally inherited UBE3A allele. In neurons, UBE3A is imprinted with maternal-
specific expression, thus leaving the paternal allele transcriptionally inactive but geneti-
cally intact. As such, approaches to reactivate expression of the paternal allele are seen as
a viable therapeutic option for AS. ES cells with a paternally inherited Ube3aY FP reporter
allele were generated to perform proof-of-concept HTS. Imprinted paternal Ube3aY FP is
reactivated after treatment with Topotecan, a topoisomerase inhibitor known to reactivate
the silenced paternal allele. These initial results demonstrate the utility of ES-N to perform
HTS to identify novel therapeutics for neurological disorders.
4.2 Introduction
High-throughput screening (HTS) of drug libraries, small molecule compounds, and
biologicals is a powerful approach to identify new therapies for a wide rand of diseases
[102,188–194]. While most high-throughput drug discovery assays are relatively straight-
forward, those aimed at identifying new therapies for diseases of the central nervous sys-
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tem (CNS) are difficult because of the challenges associated with using neuronal cell-
lines. Indeed there are numerous sources of immortalized neuronal cell-lines (e.g., P19,
SH-SY5Y neuroblastoma cells, NT2, PC12 cells, etc.), but genetically modified mouse
primary neurons are the most appropriate cell-line for performing high-throughput drug
discovery screens for monogenic disorders [195–203]. Methods currently used to estab-
lish mouse primary neurons involve immature neurons isolated from either prenatal (e.g.,
E15-E18) or early postnatal (e.g., P1-P2) brains. As such, scheduling experiments is en-
tirely dependent on the breeding schedules and availability of mice.
The number of neurons obtained from the mouse brain is also rather limited; for ex-
ample, current studies estimate that approximately 600,000 neurons per hippocampi and
800,000 neurons per cortices can be cultured per mouse brain [204]. Primary neuronal cul-
tures are typically grown at 20,000 cells/well [52], approximately 7:68  106 cells would
be needed for one 384-well plate. Mouse neural stem cells can be expanded in vitro, but
they can only be maintained in an undifferentiated state for a finite period of time, and
they yield low percentages of neurons after differentiation. Another challenge is that most
HTS facilities do not accommodate experiments involving primary cell cultures because of
the risks associated with contaminating other cell-lines (personal communication Clifford
Stephen). Altogether, high-throughput drug discovery efforts for neurological disorders
are met with numerous technical challenges that have likely impeded drug discovery ef-
forts.
Mouse embryonic stem (ES) cell-derived neurons are an ideal alternative to primary
neuronal cultures. Mouse ES cells rapidly divide in vitro and can be maintained in an
undifferentiated state almost indefinitely. They are amendable to targeted genetic mod-
ifications or can easily be generated from existing transgenic models [205–208]. They
are commonly used in HTS assays and accepted by most HTS facilities [209]. Impor-
tantly, ES cells can be reliably and efficiently differentiated into neuronal cell populations
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that exhibit gene expression patterns, epigentic marks, and electrophysiological properties
similar to mouse primary neurons [210–214]. Their use in high-throughput drug discovery
assays, however, has been underutilized [215–219].
Angelman syndrome (AS) is a debilitating neurodevelopmental disorder characterized
by severe intellectual disability, absent speech, ataxia, seizures, frequent smiling and in-
appropriate laughter [2, 3, 26]. The genetic or epigenetic mutations causing AS are as-
sociated with loss of maternal - but not paternal - expression of the ubiquitin ligase E3A
protein gene (UBE3A). The non-Mendelian inheritance pattern of AS is due to genomic
imprinting of UBE3A [2, 3]. In almost all cell-types, UBE3A is expressed from both
parental alleles; however, in the brain, UBE3A is perferentially expressed from the ma-
ternal allele [34]. Expression of the paternal UBE3A allele is inhibited by the antisense
expression of a long polycistronic transcription unit (PTU) that is comprised of SNURF-
SNRPN, clusters of C/D box small nucleolar RNAs (SNORD64, SNORD109, SNORD116,
and SNORD115), and the UBE3A antisense transcript (UBE3A-AS) [35, 36]). Studies in
mice show that Ube3a is imprinted in neurons, including ES cell-derived neurons, and
biallelically expressed in other cell-types of the brain [31–34], which is consistent with
the neuron-specific expression of UBE3A-AS.
Currently, there are few treatment options for Angelman syndrome patients. Available
treatments for those with Angelman syndrome focus on behavioral and physical therapies
to minimize symptoms, along with drug therapies to control seizures and sleep disruption.
Since the inactive paternal UBE3A allele is genetically intact but epigenetically silent,
approaches to reactivate expression of the paternal UBE3A allele are therefore seen as
viable therapeutic options to treat AS. In fact, recent studies in mice have shown that phar-
macological, genetic, and epigenetic methods are all capable of reactivating expression
of paternal Ube3a expression in primary neurons and the adult mouse [36, 52, 123, 125].
Importantly, there appears to be some degree of improvement of symptoms after reactiva-
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tion [124–127].
In this study, we established and validated a fluorescence based HTS assay in ES cell-
derived neurons (ES-N) with an Ube3aY FP reporter allele. We demonstrate the utility of
this approach for performing large-scale, high-throughput drug discovery assays to iden-
tify novel therapies to treat Angelman syndrome.
4.3 Materials and Methods
4.3.1 Animals
Animals housed under the standard conditions, pathogen-free mouse facility. All pro-
cedures performed according to NIH guidelines and approved by the Texas A&M Univer-
sity Institutional Animal Care and Use Committee (IACUC). The laboratory of Dr. Arthur
Beaudet generated and provided Ube3aY FP mouse model [128]. All mice maintained on
C57BL/6J background (The Jackson Laboratories, Bar Harbor, ME).
4.3.2 Generation of Ube3a+=Y FP embryonic stem cells
MouseUbe3a+=Y FP ES cells were established following standard methods [220–224].
Briefly, Ube3aY FP=Y FP males were mated to three to four week old C57BL/6J superovu-
lated female mice. Females were superovulated via 5 I.U. of pregnant mares serum go-
nadotropin (PMSG) in 0.1 ml of PBS followed by 5 I.U. of human chorionic gonadotropin
(hCG) 46 h later. Embryos (E2.5) collected from oviducts were cultured overnight in one
well of a 4-well plate (Thermo Scientific, Waltham, MA) in KSOM Evolve (IVFonline,
Guelph, Canada) containing 1 mg/ml bovine serum albumin (Sigma-Aldrich, St. Louis,
MO). The following day, individual embryos were transferred and cultured for four days in
30 l microdrops of KORS+2i medium covered by mineral oil (37C, 5% CO2) [223,225].
After 96 h in KOSR-2i medium, outgrowths were trypsinized using 0.25% Trypsin-EDTA
(Life Technologies, Carlsbad, CA) into single-cell suspensions and plated individually in
96-well, flat bottom, tissue culture treated plate (Corning Inc., Corning, NY) containing a
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mitomycin-C inactivated SNL 76/7 feeder cells monolayer [226–229] (Applied StemCell,
Inc., Milpitas, CA) at 50,000 cells/cm2 and KOSR-2i preconditioned (>2 h) medium.
Cells were incubated (37C, 5% CO2) for four days with daily changes of medium. To
establish ES cell-lines, undifferentiated colonies were gradually expanded and genotyped
using Jackson Laboratory genotyping primers for Ube3aY FP : 5’ TCAATGATAGGGA-
GATAAAACA 3’, 5’ GAAAACACTAACATGGAGCTC 3’, and 5’ CTTGTGTAGCGC-
CAAGTGC 3’. Of the six lines tested for ES cell growth, lines #2 and #10 were selected
for further large-scale expansion resulting in 43 vials at 3:5  106 cells/vial each. The
following studies were conducted using line #10 (Appendix D, Figure D.1).
4.3.3 Neuronal Differentiation
Retinoic acid (RA) based-induction methods [230–232] with slight modifications for
high-throughput screening purposes directed differentiation of Ube3a+=Y FP ES cells into
neuronal cultures. Briefly, 1 vial of frozen Ube3a+=Y FP ES cells (approx. 3:5  106
cells) were expanded in ES preconditioned (>2 h) medium (Appendix D, Table D.1)
on 60-mm plates (Corning, Inc.) of mitomycin-C treated SNL feeder cells adhered to
0.1% gelatin (STEMCELL Technologies Inc., Cambridge, MA) for two passages. ES
cells were separated from SNL feeder cells via a 30 min incubation at room temperature
on T175 flasks (Thermo Scientific) in ES medium. Cells were counted and plated in
suspension in CA medium (Appendix D, Table D.1) on six 100-mm bacteriological plates
(Greiner Bio-One, Kremsmünster, Austria) at 4  106 cells/plate. The following day, the
CA medium was changed and cellular aggregates (CAs) were split 1:2 by transferring
the cell suspension into 50 ml tubes (1 plate/tube). The CAs settled via gravity (>= 3
min), and supernatant was removed and replaced with 20 ml of CA medium. The cells
were gently pipetted to mix and plated at 10 ml per plate. After 48 h in suspension, CAs
were split again (1:2) as described above and media changed to CA medium containing
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retinoic acid (Sigma-Aldrich) at a final concentration of 0.5 mM. For the next four days,
CA medium with RA was changed daily.
For the dissociation step, ES cell-derived neurons cellular aggregates were transported
to HTS facility (37C, 2 h) or dissociated immediately in the lab. In both instances,
cells were dissociated with 0.5% Trypsin-EDTA and plated in N2 medium, Appendix D,
Table D.1 on 384-well poly-d-lysine coated optical bottom plates (Thermo Scientific) at
24,000 cells/well using a microplate washer (Tecan Group Ltd, Männedorf, Switzerland)
for HTS or 18 mm round coverslips (VWR, Radnor, PA) coated with poly-l-ornithine
(Sigma-Aldrich) and laminin (Life Technologies) at 4105 cells/well for imprint analysis.
Stocks of 0.5 mg/ml poly-l-ornithine in 150 mM boric acid were diluted 1:5 in purified wa-
ter to coat overnight at 4C. After coverslips were rinsed three times with cell culture grade
water, laminin (10 g/l) was added to the coverslips and incubated at 4C overnight. Af-
ter 48 h, media was changed to Complete medium, Appendix D, Table D.1. Every three
days Complete medium was changed. Eight days post dissociation (DPD), compounds
were added and maintained for 72 h. Topotecan hydrochloride (Sigma-Aldrich) was dis-
solved in water (10 mM stock) and then diluted to 3 M into DMSO (Sigma-Aldrich) for
HTS, while 10 M stock in water was used for imprint analysis. Topotecan hydrochlo-
ride was added to the Complete medium at 300 nM final concentration along with vehicle
(DMSO or water) using microplate washer for HTS or by-hand for imprint analysis as
positive and negative controls, respectively.
4.3.4 Immunocytochemistry
Immunocytochemistry and staining were performed as described previously [233].
Briefly, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) for HTS or 4% parafo-
rmaldehyde / 4% sucrose (Sigma-Aldrich) for imprint analysis (10 min, RT). For high-
throughput drug screening, cultures were blocked in 5% goat serum (Sigma-Aldrich) and
59
0.3% Triton X-100 (Sigma-Aldrich) for 15 min at 37C, while imprint analysis blocked
for 1 h at room temperature. Primary antibody was diluted in antibody buffer containing
5% goat serum and 0.3% Triton X-100 and incubated for 1 h at room temperature or for
30 min at 37C for the high-throughput screen. Cells were washed three times before sec-
ondary antibody incubation with 0.1% Tween20 (Sigma-Aldrich) for 10 to 15 min at room
temperature. Primary antibodies used here are as follows: anti-GFP (Novus Biologicals,
Inc., Littleton, CO), anti-NeuN (EMD Millipore) and anti-III Tubulin (Sigma-Aldrich).
Secondary antibodies used was Alexa Fluor 488, goat anti-rabbit, and Cy3 goat anti-mouse
(Jackson Immuno Research Labs, West Grove, PA). Secondary antibodies were incubated
in 5% goat serum and 0.3% Triton X-100 for 1 h at room temperature for imprint analysis
or for 30 min at 37C for high-throughput screening. TO-PRO-3 stain (Life Technolo-
gies) at 1:1000 dilution was used for nuclei staining. Images were captured using IN Cell
6000 (GE, Schenectady, NY), and confocal images were captured using Zeiss 510 META
Confocal Microscope (Zeiss, Oberkochen, Germany).
4.3.5 Image analysis
4.3.5.1 Imprint analysis
For imprint analysis, FIJI (FIJI is just Image J, open source, https://fiji.sc/)
was used in image preparation and to measure gray scale values of individual neurons
[234, 235]. Positive III tubulin staining identified neurons. The Ube3aY FP fluorescence,
GFP staining, of each neuron was expressed as YFP intensities overlapping neuronal TO-
PRO-3 staining. Two-tailed unpaired Student’s t-test was used to determine statistical
significance when comparing two groups. To determine statistical significance for the




Image analysis for high-throughput screening was performed using IN Cell Developer
Toolbox 9.3.1. The TO-PRO-3, nuclei marker, and the NeuN, mature neuron marker, were
used to generate a neuron specific overlapping mask, (NeuN-Overlap), which was used to
measure median YFP intensity in each target. Several R scripts (Appendix D) were devel-
oped to analyze data rapidly for plate effects, within plate effects, and assay statistics. The
Shapiro-Wilk test was used on randomly selected wells for each plate to determine normal-
ity of Vehicle and Topotecan treated cells. Normal Q-Q plots were used to visualize nor-
mality. To determine statistical significance between plates, one-sided unpaired Student’s
t-test was used (multiple comparisons, Holm-Bonferroni method), along with the strictly
standardized mean difference (SSMD). To determine statistical significance within plate,
two-tailed unpaired Student’s t-test was used. Tomake batch analysis user friendly, a Shiny
app was developed (kj-benjamin90.shinyapps.io/angelman-hts-app/).
4.3.6 Charts
Charts designed in R (version 3.2.2 [161]) programming using the tikzDevice and
pdf functions from the devtools package. Appendix D shows sample scripts.
4.4 Results
4.4.1 Topotecan induces reactivation of silenced paternal Ube3a allele in ES cell-derived
neurons
It has been established that ES-N can recapitulate the paternal imprint in ES cells [35,
236]; however, a time course for this paternal imprint has not been established to the best
of our knowledge. Here, we verified paternal imprint of Ube3a via a 13 day time course to
determine the days post dissociation (DPD) needed for the imprint to be established in this
cell-line. Figure 4.1A shows that after 6 days in culture paternal Ube3aY FP expression
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significantly decreased (Table 4.1, Holm-Bonferroni) and continues to maintain a low
level of expression. By 13 DPD the ES-N sustain the paternal Ube3a imprint as shown in
Figure 4.1B. Thus, demonstrating that our cell-line also recapitulates the paternal imprint
of Ube3a as early as 6 DPD.
In addition to developing a time course for Ube3a paternal imprinting, we demonstrate
in Figure 4.1C that Topotecan, a drug proven to reactivate the paternal Ube3a in primary
neurons via inhibition of topoisomerase (Appendix D, Figure D.2), could also reactivate
the paternal allele in embryonic stem cell-derived neurons. This confirmed that Topotecan
can act as a positive control for our embryonic stem cell-based HTS assay.
Table 4.1: P-values for time course analysis
2 DPD 4 DPD 6 DPD 8 DPD 12 DPD
4 DPD 0:75 - - - -
6 DPD 4:0 10 5 7:3 10 7 - - -
8 DPD 3:5 10 5 6:2 10 7 1:00 - -
12 DPD 2:2 10 8 3:4 10 10 0:24 0:24 -
13 DPD 4:4 10 8 6:9 10 10 0:28 0:28 1:00
4.4.2 Plate effect is not observed for the NeuN-Overlap method
To determine if image acquisition time effects the YFP intensity, plate statistics were
calculated and plotted in Figure 4.2. Over the course of roughly 12 h, assay stability
remains the same with large separation between Vehicle and Topotecan. P-values from the
Student’s T test were significant for all plates with no correlation over time, Table 4.2. For
quality control of assay, the z factor (Z Factor) was calculated, Table 4.2; however, since










































































Figure 4.1: Topotecan induces reactivation of paternal Ube3a allele in ES cell-derived
neurons. A) Boxplots of time course analysis of imprinted neurons (N = 10). B) Boxplots
of Ube3aY FP ES cell-derived neurons at 2 and 13 days post dissociation (DPD) demon-
strating the imprinting of paternal Ube3a. C) Boxplots of ES cell-derived neurons at 13
DPD with vehicle (water) or Topotecan (300 nM) treatment demonstrating the reactivation















































































































































Figure 4.2: The decrease in Ube3aY FP intensity as a function of time does not effect
separation of Topotecan intensity from Vehicle.
for each plate had non-normal distributions (Shapiro-Wilk, p-value < 0.05, Appendix
D, Table D.2), the strictly standardized mean difference (SSMD, ^) was also calculated,
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Table 4.2. Q-Q plots shown in Appendix D.
Zfactor = 1  3(~p + ~n)j~p   ~nj ;
where ~ and ~ are sample standard deviations and sample means, respectively, for positive









where ~X and ~s are medians and median absolute deviations in the positive and negative
controls, respectively [238,239].
Although assay quality remains the same over time, there is a slight decrease in YFP
intensity over time. As a high-throughput assay, plates are often run in large quantities.
To determine a theoretical number of plates that can be run at one time, linear regression
models were estimated as a function of time for Vehicle YFP intensity (R2 = 0:9645) and
Topotecan intensity (R2 = 0:7768). Each plate has roughly 90 min separating them as
determined from acquisition log information.
y(Topotecan) =  0:38t+ 1911 and y(V ehicle) =  0:36t+ 879
Set max Vehicle to equal Topotecan to determine when time adversely effects the assay.
879 =  0:38t+ 1911







At roughly 90 min image acquisition time, NeuN-Overlap method could ideally run 30
plates assuming antibody decay rate is not exponential. Using more conservative param-
eters, three times the mean standard deviation of both Topotecan (T) and Vehicle (V), the
stability of data acquisition as a function of time is calculated below:
y(T ) =  0:38t+ 1911  (3 139:3) and y(V ) =  0:36t+ 879 + (3 67:0)
1080 =  0:38t+ 1493





At roughly 90 min image acquisition time, NeuN-Overlap method can conceivably run
12 plates.
Table 4.2: P-values for NeuN-Overlap plate effect analysis
T-test Z factor SSMD
Plate-1 1:43 10 27 0:335 5:89
Plate-2 3:08 10 36 0:526 9:28
Plate-3 2:68 10 31 0:324 7:54
Plate-4 8:24 10 38 0:436 8:37
Plate-5 1:13 10 30 0:311 7:49
Plate-6 6:37 10 21 0:136 5:87
Plate-7 3:24 10 26 0:433 6:98
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Table 4.2: Continued...
T-test Z factor SSMD
Plate-8 1:14 10 34 0:629 13:65
Plate-9 1:63 10 28 0:389 7:34
4.4.3 Well position effects Ube3aY FP intensity
To determine if well position effected YFP intensity measured, wells with vehicle from
column 1 were compared with vehicle from column 24, and Topotecan wells from column
2 were compared with Topotecan wells from column 23. The p-values from the two-tailed
Student’s T-test are shown in Table 4.3. Only two plates for Vehicle show well position
effects, while Topotecan wells have nearly half showing significant differences between
positions within the plate.













In this chapter, the high-throughput screening method using embryonic stem cell-
derived neuronal cultures is validated via proof-of-concept screening for Angelman syn-
drome. Embryonic stem cells were generated from reporter mice Ube3a+=Y FP [128] and
expanded. The expansion of these ES cells provides a large pool of available ES cells at the
same time point for further differentiation. The neurons derived from these ES cells were
significantly more than those that can be collected from primary cultures with on average
600 106 from 6 initial neuronal induction plates. For neurons obtained from embryonic
mice, the generation of animals presents a major bottleneck for high-throughput screen-
ing. Even with recent advances in neuron mini-cultures, 1 million cells can only plate little
more than four 384-well plates [240]. To compare, mini-cultures would still require more
than 200 embryos with excellent culturing techniques to generate similar numbers.
As research has shown that paternal Ube3a is imprinting during development, the time
point of imprinting of paternal Ube3a in culture was determined for the HTS assay. We
determined that within six days Ube3aY FP significantly decreased. For the HTS assay,
drugs were added 7 DPD for convenience of HTS facility. Nine 384-well optical-bottom
plates were run with Vehicle, columns 1 & 24, and Topotecan, columns 2 & 23, added to
the plate using a 300 drugs/small molecule compounds drug loading model. At roughly
30 min/antibody, the total plate image acquisition time was approximately 90 min/plate,
which is longer than most HTS that commonly only image with a single antibody. As
such, there was some concern that antibody intensity would significantly decrease over-
time; however, using the NeuN-Overlap, which is specific to mature neurons, there was
no significant decrease observed. Even so, it is this author’s recommendation that only 12
plates be run in one sitting assuming that acquisition time is approximately 90 min.
All plates showed significant difference between Vehicle and Topotecan controls, Ta-
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ble 4.2; however, only two plates had a z factor of  0.5, which indicates an Excellent
assay [237]. This may be due to the outliers observed in Figure 4.2 as the z factor cal-
culation is not robust to outliers [241]. As an alternative, the strictly standardized mean
difference method specific to outliers robustness was also calculated per plate with an aver-
age ^ of approximately 8.04, where ^ > 7:0 is an Excellent assay for HTS small molecule
assays [238]. Altogether using the outliers robust SSMD method, this HTS assay scores
an Excellent for quality control.
Finally, this work is directly applicable for performing a high-throughput screen for
Angelman syndrome. Currently, the only drug known to reactivate the paternal Ube3a
allele is Topotecan. This drug, however, is extremely toxic and currently approved as a
chemotherapeutic. Therefore, an alternative therapeutic drug is still needed. Furthermore
with this ES cell-derived neuronal culture HTS assay, it will be possible to conduct an RNA
interference screen for pathway analysis of the imprint of Ube3a. With such a screen,
additional targets for therapeutic intervention for Angelman syndrome can possibly be
determined. In summary, this data shows that ES-N model can dramatically increase the
scale of screening studies for neurological disorders.
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5. CONCLUSION
Recent studies show that the human brain has one of the most complex expression pat-
terns of the body. The expression patterns of the imprinted region 15q11-13, containing
UBE3A and UBE3A-AS, are no exception. The studies herein explore the unique im-
printing of paternal UBE3A/Ube3a in neurons. Specifically, we were able to demonstrate
that both mouse and human Ube3a-AS/UBE3A-AS are extensively processed via bioin-
formatics and molecular analysis; demonstrating spatiotemporal regulation of Ube3a-AS.
For both mouse and humans, we sequenced 3’ RACE clones verifying polyadenylation
sites within the antisense region of Ube3a/UBE3A. This finding suggesting that dosage
sensitive UBE3A may be imprinted in neurons so that sense and antisense transcripts are
co-expressed in the brain. Additionally, the temporal regulation of Ube3a-AS suggest it
may play a role in the developing brain. Following these experiments, we demonstrated
the existence of a fourth paternal-specific Ube3a isoform in mice generated via alternative
polyadenylation at novel exon 4.1. In the investigating of this novel isoform, we demon-
strated that its expression corresponded with Ube3a-AS expression suggesting an alter-
native mechanism of paternal Ube3a imprinting. Simultaneously, we developed a high-
throughput screening method in embryonic stem cell-derived neurons; demonstrating its
potential for drug discovery for neurodevelopmental disorders like Angelman syndrome.
Taken together, these results suggest the lncRNA, UBE3A-AS, may have additional regu-
latory functions outside of the imprinting of UBE3A and that the novel isoform 4 may also
serve as a regulatory RNA. Moreover, they also propose an alternative mechanism of im-
printing for Ube3a, wherein by some unknown mechanism Ube3a-AS causes termination
and polyadenylation of paternal Ube3a transcription. Finally, these results setup future
drug discovery experiments for Angelman syndrome.
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5.1 Ube3a-AS demonstrates complex expression within the brain
The antisense transcript of UBE3A, identified in 1998, originates from the 3’ end of
a large polycistronic transcriptional unit consisting of SNURF/SNRPN, IPW, and a clus-
ter of snoRNAs [31–33, 37]; however, UBE3A-AS is only expressed in neurons. While
Ube3a-AS is sufficient to repress the expression of Ube3a in neurons [35, 36], our find-
ings showed temporal regulation only for Ube3a-AS and Ube3a isoform 4, suggesting
Ube3a-AS expression is unrelated to the imprinting of Ube3a and therefore may be a by-
product of another regulatory process. In fact, additional work in our laboratory showed
that maternal Ube3a expression increased as paternal expression decreased keeping overall
Ube3a expression constant [54]. Further investigation into UBE3A-AS/Ube3a-AS expres-
sion revealed that the antisense transcript was alternatively spliced generating dozens of
transcripts in the mouse and at least ten transcripts in the human with several polyadenyla-
tion sites and 5’ capping events. In the mouse, we confirmed RNA-seq analysis that these
isoforms were differentially expressed between brain regions. Furthermore, we found that
Ube3a-AS generalized isoforms 1 and 2 along with Ube3a isoform 4 were temporally
regulated in the hippocampus, showing upregulation during post-natal development.
These findings contradict current Ube3a-AS theories mainly because of differing ap-
proaches in analyzing the 15q11-13 imprinted region. Here, we used powerful high-
throughput sequencing technologies, specifically stranded paired-end RNA-seq, to gen-
erate transcriptional profiles where sense and antisense transcripts could be distinguished.
Additionally, we used the hybrid C57xDBA mice from public data to further distinguish
allelic contributions. As such, we were able to analyze the imprinted region in a more
detailed and rigorous manner than other studies, and in doing so our findings showed spa-
tiotemporally regulation of Ube3a-AS.
Spatiotemporal regulation used to generated specialized tissues during development in
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a highly dynamic environment like the brain. For instance, genes associated with temporal
regulation during early embryonic development are grouped into categories involving neu-
ron differentiation, axonogenesis, and forebrain development, which are often connected
to proper morphological growth [242]. Furthermore, temporally regulated genes asso-
ciated with late post-natal development involve the regulation of synaptic transmission,
behavior, and learning and memory [242]. As such, the upregulation of Ube3a-AS during
post-natal development, is in agreement with the imprinting of Ube3a and the phenotypes
associated with neurodevelopmental disorders of the imprinted 15q11-q13 region. More-
over, the uniqueness of cerebellum temporal gene expression is also reflected in our results
with differential expression of the isoforms within the brain regions [242–244]. As such,
it is also possible that the generalized Ube3a-AS isoform 3 could be temporally regulated
in the cerebellum, where its expression is upregulated. Altogether, these results suggest a
regulatory function for UBE3A-AS.
The implications of UBE3A-AS having additional functions potentially impacts the
current therapeutic strategy for Angelman syndrome. Since the inactive paternal UBE3A
allele is genetically intact but epigenetically silent, recent studies have targeted the paternal
Ube3a for reactivation via disruption of Ube3a-AS [36,52,123–126]; however, if UBE3A-
AS has additional regulatory functions, disruption of the lncRNA could adversely effect
other pathways that UBE3A-AS may play a role in. It is for this reason, that UBE3A-AS
should be intensively studied to better understand any potential ramification of disrupting
its expression as a treatment for Angelman syndrome.
5.2 Ube3a-AS generates a paternal, neuron-specific, Ube3a isoform - isoform 4
Previous investigations into the expression of Ube3a-AS revealed partial expression of
paternal Ube3a [35, 122]. This phenomenon along with ChIP-on-chip experiments con-
firming that both Ube3a promoters are enriched with chromatin modification (histone H3
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lysine 4 trimethylation), bound by RNA polymerase II, and actively transcribed gave rise
to the collision model as a mechanism of paternal Ube3a [36] imprinting in neurons. In
this model, RNA polymerase II from Ube3a sense-strand and Ube3a-AS antisense-strand
collide causing a gradual decrease in expression resulting in partial paternal Ube3a ex-
pression, Figure 1.12A. As noted in Chapter 1, this model implies that Ube3a-AS is
not expressed past the collision within intron 4 of Ube3a, which is not in agreement
with Numata et al. SNP data showing paternal RNA expression upstream the Ube3a
primer [122]. From our Ube3a-AS isoform annotations (Figure 2.1) several assembled
transcripts aligned with Numata et al. SNP data upstream the Ube3a promoter, suggest-
ing that Ube3a-AS RNA polymerase does not stall within Ube3a gene. Furthermore, we
identified and verified a fourth Ube3a isoform that terminates within intron 4 in agreement
with previous studies [35, 122]. Altogether suggesting an alternative model of imprinting
alternative polyadenylation, wherein Ube3a-AS though some unknown mechanism leads
to alternative exon usage, exon 4.1, and termination of Ube3a transcription.
Alternative polyadenylation (APA) is a widespread phenomenon within humans that
generates isoforms with alternative 3’ ends. Moreover, APA events occur commonly dur-
ing development and cellular differentiation in a tissue-specific manner [245]. For exam-
ple, BDNF, or brain-derived neurotrophic factor, is one such brain-specific sense/antisense
gene that involves APA to produce short and long 3’ UTR isoforms [246, 247]. Although
unlike the proposed Ube3a/Ube3a-AS model, BDNF APA sites are within the 3’ UTR.
Even so, this type of alternative polyadenylation, terminal exon APA usage hypothesized
in Figure 1.12B is known to be associated with splicing and APA machinery [248]. In
the Ube3a/Ube3a-AS example, a weak 5’ splicing site within the long intron 4 leads to
dynamic competition between splicing and polyadenylation [249], which causes the alter-
native polyadenylation within intron 4 - paternal Ube3a isoform 4.
With the understanding that tissue-specific APA is not a unique phenomenon, we pro-
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posed three possible reasons for the imprinting of Ube3a in neurons. The first involves
the importance of paternal Ube3a isoform 4 caused by APA. Here, isoform 4, like many
APA isoforms, could change microRNA binding sites [250], or potentially code for a new
protein [251,252]. Additionally, changes in 3’ UTR have effects to stability, cellular local-
ization, and translation efficiency [253, 254], all of which effect RNA functionality. The
second reason could be that Ube3a-AS has tissue-specific regulatory functions and the im-
print evolved to express both Ube3a and Ube3a-AS. Finally, it is possible that Ube3a-AS
and Ube3a isoform 4 expression have regulatory roles in brain development. Neverthe-
less, there are clear ramifications for current Angelman syndrome drug therapy strategies
as discussed above.
Even so, the revelation of alternative polyadenylation generating paternal Ube3a iso-
form 4 opens the door for an alternative approach to AS drug therapies like exon skip-
ping. Exon skipping is a form of RNA splicing used to restore reading frame within a
gene and can be experimentally done via antisense-mediation. Antisense-mediation uses
antisense oligonucleotides to hybridize to a sense target sequence leading to RNase H
cleaving and gene-specific knockdown [255]. For exon skipping purposes, the antisense
oligonucleotides are modified to act on pre-mRNA splicing by blocking splicing signals
and induces exon skipping [256]. Currently, this technique is being used in phase III clin-
ical trials held by Sarepta Therapeutics for Duchenne muscular dystrophy (DMD) [257].
As DMD is often caused by mutation that disrupt the open reading frame, exon skipping
is used to modulate splicing of DMD gene to restore the reading frame [258–260]. Since
Ube3a isoform 4 uses an alternative exon, exon 4.1, that terminates transcription, anti-
sense oligonucleotides can be designed to skip exon 4.1 and possible produce a full-length
paternal Ube3a transcript.
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5.3 Embryonic stem cells are a versatile source for high-throughput screening
In Chapter 4, embryonic stem cells were used to generate neurons ultimately for HTS
for Angelman syndrome. These ES cells were relatively easy to generate and expand
for large-scale studies unlike primary neurons, which have a finite number of cells per
animal. Additionally, ES cells from Ube3a+=Y FP mice housed in the laboratory were
produced within months demonstrating the modularity of the HTS method. While ES cell-
derived neuronal cultures generate significantly more cells than primary cultures, there are
other sources of immortalized neuronal cell-lines (e.g., P19, SH-SY5Y neuroblastoma
cells, NT2, PC12 cells, etc.) that could potentially do the same; however, iPS (induced
pluripotent stem) cells are the only immortalized cell-line surging in popularity for HTS
purposes [261–263].
One of the major benefits of using human iPS cells over ES cells (human or mouse)
is the ability to use patient-specific cells. As these cells are derived from postnatal so-
matic cells [264, 265], they can be collected directly from diseased individuals for more
biological complex drug screenings. While the advantages of using iPS cells over ES
cell appear abundantly clear, especially for translational medicine applications, there are
still several concerns with the use of iPS cells including functionality and chromosomal
aberrations and genetic modifications. For example, recent studies have shown variabil-
ity in iPS neurons differentiation efficiency compared to more consistent differentiation
using ES cells [266]. Moreover, high-resolution genetic and epigenetic analysis revealed
differences between iPS and ES cells including DNA methylation and expression pro-
files [267, 268], which could effect the ability of iPS cells to recapitulate certain diseases
accurately. Although it is not clear what these results mean, more research is required to
understand which stem cell-line is better suited for HTS.
Moving forward with HTS in ES cell-derived neurons, three key recommendations are
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provided. 1) Test multiple lots of NeuN antibody before purchasing in bulk (> 20 vials).1
2) Run no more than 12-13 plates in one setting.2 3) Always add positive (Topotecan) and
negative (Vehicle) controls to each plate for quality control.
5.4 Future studies
5.4.1 Investigation of Ube3a-AS/UBE3A-AS predicted transcripts
5.4.1.1 PacBio
While we were able to several polyadenylation sites of UBE3A-AS/Ube3a-AS, the ma-
jority of the predicted transcripts have yet to be identified. Moreover, we were unable
to verify full-length transcripts with the short-read RNA-seq. To circumvent short-read
problems for isoform sequencing, full-length cDNA sequences can be generated using
PacBio long-read technologies to determine the exact number of isoforms, the degree of
interconnection between upstream snoRNAs, and exon usage between isoforms.
5.4.1.2 circRNAs
In both human and mouse assemblies of the antisense region, transcripts that appeared
to be circular RNAs (circRNAs) visually were detected. These transcripts showed signif-
icant brain-specific expression compared to the generalized isoform categories for human
and mouse. First, bioinformatic algorithms like STAR circRNA function [269] or by fol-
lowing Memczak et al. protocol [270] to predict circRNA and cross-referenced with the
databases of annotated circRNAs [271]. Their expression can then be verified with qPCR
techniques as described in Li et al. (2017) [272]. Briefly, total RNA would be digested
with RNase R and purified with phenol-chloroform extraction to be used in cDNA reac-
tion and subsequent circRNA specific qPCR assays [270]. Results from these experiments
1NeuN antibody varied greatly depending on lot number
2Assuming image acquisition is approximate 90 min/plate, otherwise, plate number should be adjusted
accordingly.
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would provide additional support for regulatory functions of UBE3A-AS/Ube3a-AS.
5.4.2 Additional verification of Ube3a-AS control of Ube3a isoform 4 expression
As Topotecan is known to effect alternative splicing [184,185], additional experiments
that are Ube3a-AS specific could also be conducted. One means of doing this is by using
antisense oligonucleotides (ASOs) like Meng et al. (2013) [36]. These ASOs can be used
to treated primary neuronal cultures and qPCR can be conducted similarly to Topotecan
treated neurons inChapter 3. In addition to ASOs, a PWS-IC deletion transgenetic mouse
model could be used. For this approach, RNA would extracted from transgenetic mouse
brains and expression could be measured with RT-PCR. Results from these experiments
would provide additional support for the control of alternative polyadenylation of Ube3a
isoform 4 by Ube3a-AS.
5.4.3 Molecular analysis of Ube3a-AS and Ube3a isoform 4
5.4.3.1 RNA stability analysis
Recent studies investigated the processing ofUbe3a-AS determined thatUbe3a-ASwas
an atypical RNAPII transcript [35]; however, we found that the antisense primers listed in
the publication targeted introns of the spliced Ube3a-AS predicted by our RNA-seq anal-
ysis. As such, the processing of Ube3a-AS should be re-evaluated for polyadenylation,
cellular localization, and stability. To test polyadenylation, processed mRNA can be com-
pared to total RNA with quantitative PCR similar to Meng et al. (2012) [35]. To test local-
ization of sense and antisense transcript, RNA FISH (fluorescence in situ hybridization)
can be used on generalizedUbe3a-AS isoforms andUbe3a isoform 4. This would allow for
visualization of these transcripts at the sub-cellular level in a quantifiable manner. Stellaris
offers several protocols for performing RNA FISH on their website (https://www.
biosearchtech.com/support/resources/stellaris-protocols). Finally,
RNA stability can be determined via half-life experiments on actinomycin D treated pri-
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mary neuronal cultures as previously described [35].
5.4.3.2 Temporal regulation of the antisense transcripts
The temporal regulation analysis was limited to mouse hippocampal neurons, as such,
addition molecular experiments could be conducted to look at temporal regulation in
mouse cerebellum with qPCR techniques. Furthermore, temporal regulation in the human
brain can also be investigated with publicly available RNA-seq data [273]. Both analysis
could be used in conjunction with the Allen Brain Atlas to determine possible pathways
for the Ube3a-AS/UBE3A-AS.
5.4.3.3 RNA Co-Immunoprecipitation
In addition to the temporal expression analysis, RNA co-immunoprecipitation to eluci-
date possible RNA-protein interactions for Ube3a-AS and Ube3a isoform 4. Jedamzik and
Eckmann (2009) provide a full protocol for analyzing RNA-protein complexes by RNA
co-immunoprecipitation [274]. Results from this study could be also be used in pathway
analysis.
5.4.4 Exon skipping of Ube3a isoform 4 as a therapeutic strategy for Angelman syn-
drome
The identification of a paternal-specific Ube3a isoform generated from alternative
polyadenylation offers the potential of an alternative therapeutic strategy for Angelman
syndrome, exon skipping. While not a trivial strategy, there is a comprehensive proto-
col book for exon skipping [275]. In brief, potential splice sites and cis-regulatory ele-
ments (i.e. exonic and intronic splicing enhancer sequences) would first be identified via
open-source software like ESEfinder 3.0 [276, 277]. Following identification, a splicing
functional assay based on minigenes would be used, where the exonic fragment surround
Ube3a exon 4.1 is amplified and cloned into a splicing competent minigene vector. If suc-
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cessful, the antisense oligonucleotides used in the in vitro splicing assay can be optimized
for animal models. Furthermore, the protocol book edited by Aartsma-Rus has several
protocols to help with troubleshooting and optimization of exon skipping.
5.4.5 High-throughput screening assays
We developed and verified the ES cell-derived neuronal culture HTS method (Chapter
4). With this frame work in place, the next step is to perform a small molecule drug
screen. Following a small molecule screen, hits would be verified via a primary neuron
assay and drug dosage profile created for each positive hits. After which, animals can
be used to further verify results. In addition to this small molecule screening, an RNA-
interference HTS can also be run. Despite numerous studies into UBE3A, little is known
about its pathway in neurons. An RNA-interference screen could give some insight into
the pathways involved with the imprint of Ube3a in neurons.
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KNOWN UBE3A PROTEIN INTERACTIONS
Table A.1: Ubiquitin Functions








ATP ATP hydrolysis (Na/K
ions)
Cytosol Flies [279]





Blk Tyrosine kinase Golgi; cytosol Human T
cells; yeast
[281]

















Protein Description Localization Cell Type Ref






































Protein Description Localization Cell Type Ref
MCM7 DNA replication Chromosome HeLa;
yeast
[293]

























Cytosol; nuclear Mouse cell
lines
[300]
































Tuberin mTOR pathway Cytosol; nuclear HEK293T [309]












Table A.2: Co-activator Functions
Protein Description Localization Cell Type Ref
AIB1 Steroid receptor
co-activator




















Hormone response Cytosol; nuclear Mice [316]
Golgin-160 Golgi membrane
associated
Cytosol; golgi HeLa [317]
Highwire Putative E3 Ub-ligase Cytosol HeLa [317]
MC1R Skin pigmentation Cytosol;
chromosome
Mice [318]
PPAR Lipid and glucose
metabolism
Cytosol; nuclear Mice; FaO [319]
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Table A.3: Indirect Regulation
Protein Description Localization Cell Type Ref























MBD5 Methy-CpG-binding 5 Nuclear Patient cell
lines
[325]


























Figure A.1: Localization of UBE3A protein interactions (%)
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APPENDIX B
SUPPLEMENTAL DATA - CHAPTER TWO
B.1 Methods extended
Table B.1: Mouse tissue information by study
Study Strain Tissue Accession Read count
(million)
































frontal lobe SRR567478 186
SRR567479 159
SRP033200 Aldh1l1-EGFP astrocytes SRR1033783 29.6
SRR1033784 32.0




















Tie2-EGFP endothelial cells SRR1033795 36.5
SRR1033796 33.8









Table B.2: Human tissue information by study
Study Tissue Accession Read count (million)

















Table B.3: UBE3A-AS Primer List: ’3 RACE
Primer Name Sequence
Isoform 1, pa1 Fwd GACAGGATGGATAGATGGACAAG
Isoform 1, pa1 nested Fwd TGTAGCCAGTAGACCTATACTTTAGA
Isoform 1, pa2 Fwd CGTAAGACAACTGGCCTTTGA
Isoform 1, pa2 nested Fwd AACGCTGCTGTGGAATCTATAA
Isoform 2 Fwd CAGCTGCCAGAAAGTGAAGA
Isoform 2 nested Fwd CAGTGAACGCCAAACAAGTAAG
Isoform 3 Fwd CCTTGGGAGAGTAGTTCTGTTG
Isoform 3 nested Fwd GGCTCAACCTCAAGCAGTAATA
Table B.4: Ube3a-AS Primer List
Primer Name Sequence Reference
ActB Fwd GGCTGTATTCCCCTCCATCG [35]
ActB Rev CCAGTTGGTAACAATGCCATGT [35]
Isoform 1 Fwd GGCTCTACGAGAAGCTGACTG
Isoform 1 nxt1Fwd GATGCAGAGAATTACAGCCAAC
Isoform 1 Rev TCTGTGTCAGTCAGCTTCTCG
Isoform 1 qPCR Rev GTTGCCATCACCTTCAGTTC
Isoform 2, pa1 Fwd CTGGAACCCACTCTGTAGAC
Isoform 2, pa1 nxt Fwd ACCAGGCTGGCTTTGAAT




Primer Name Sequence Reference
Isoform 2, pa2 Fwd GGCAAGTGGGCTCATATTCT
Isoform 2, pa2 nxt Fwd CAGTCTCCATACATCCTCCTCTA
Isoform 2, pa2 Rev TCTTCCTGAGGTCCTGAGTT
Isoform 2, pa3 Fwd TGCAACACTTCCCTATTCATTTC
Isoform 2, pa3 nxt Fwd CAGGCCAAGGGTCTCTAAATC
Isoform 2, pa3 Rev GATGGTTCTTTGAGAAGATAAACCAG
Isoform 3 Fwd TGAGGCCAGATTGTTTGGGT
Isoform 3 nested Fwd CTCCCAGAAATAGAATTGGGATCA
Isoform 3 Rev GCCCTGCATTTGGCATTCAA
Isoform 3 qPCR Fwd GCTACATGCTAGGCCCTAATG
Isoform 3 qPCR Rev ATGGAGTTCTCTTGACCAAGTC
Exon 5.1 Fwd TGTTGAGGTTGGAGGATTGTC
Exon 5.2 Fwd GACCTACACTCACTGGGCAC
Exon 6 Fwd TGCTTCTTTTTGTTGCTTTCAA
Exon 7 Fwd ACAAGCAACGTTGGGAGAAC
Exon 10A Fwd CCTGCCTACCTAGCATCAGG
Exon 10B Fwd CAGCTCGCATACCCAATTTT
Exon 12A Fwd TTAACGCCAAGTTCGGTTTC
Exon 12B Fwd CTGAAGTGTTAATTCGCTGGA

































































































































































































































































































































































































































































































































Table B.5: SNP information from DBAxC57 hybrid mice
SNP Location Allelic Freq DP42
T/G Chr7:66507227 -1.0 0,0,7,6
C/T Chr7:66508429 -0.93 1,2,13,25
C/A Chr7:66508469 -0.96 1,1,30,25
G/A Chr7:66509079 -1.0 0,0,13,18
A/T Chr7:66509131 -1.0 0,0,17,13
2Position: reference forward, reference reverse, alternative forward, alternative reverse
152
B.4 Exon usage
Table B.6: Exon genomic locations for Ube3a-AS/UBE3A-AS
Isoform Chromosome Start End Strand
AS Iso1 Chr7 66,452,265 66,453,513 -
AS Iso2 Chr7 66,465,881 66,485,019 -
AS Iso3 Chr7 66,499,737 66,530,634 -
AS Isoform Chr15 25,663,935 25,667,541 +
B.5 Ballgown analysis
The custom annotation generated from stranded, high-depth reads (SRP01204) was
used for guided StringTie assembly for Ballgown ready analysis for downstream analysis
with Ballgown. Ballgown [151, 328] (version 2.6.0), a Bioconductor package, was used
to analyze the highly expressed transcripts between tissues. A CSV file with phenotype
information was generated and imported into R to generate ballgown objects. Ballgown
objects were filtered by transcription FPKM variance ( 1). The average transcript ex-





























































































































































































































































































































































































































































































































































































































































































































































SUPPLEMENTAL DATA - CHAPTER THREE
C.1 Methods extended
Table C.1: Mouse tissue information by study
Study Strain Tissue Accession Read count
(million)
































frontal lobe SRR567478 186
SRR567479 159














SRP033200 Aldh1l1-EGFP astrocytes SRR1033783 29.6
SRR1033784 32.0
















Tie2-EGFP endothelial cells SRR1033795 36.5
SRR1033796 33.8
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Table C.2: Ube3aMechanism Primer List
Primer Name Sequence Reference
ActB Fwd GGCTGTATTCCCCTCCATCG [35]
ActB Rev CCAGTTGGTAACAATGCCATGT [35]
Map2 Fwd GCCAGCCTCAGAACAAACAG
Map2 Rev AAGGTCTTGGGAGGGAAGAAC
Ube3a-AS 1 Fwd GGCTCTACGAGAAGCTGACTG
Ube3a-AS 1 Rev GTTGCCATCACCTTCAGTTC
Ube3a-AS 3 Fwd GCTACATGCTAGGCCCTAATG
Ube3a-AS 3 Fwd ATGGAGTTCTCTTGACCAAGTC
Ube3aY FP Fwd GGTGACTAATGAATCGCCCTTA
Ube3aY FP Rev GTTTACGTCGCCGTCCAG
Iso4 3’RACE Fwd CAAGGCTGACTTCAAACTCAGATA
Iso4 3’RACE nxt1Fwd TCTCCTGTTTCTGCTTTCTGAG
Ube3a Exon 4 Fwd ACCAGGAGAATCCCAGTCTGA
Ube3a Exon 4.1 Rev ATTTGATGCTGGTCATGGTG
Ube3a Exon 5 Rev TCATTCGTGCAGGCCTCATT
C.2 Gene prediction






















































































































































































































































































































































C.3 Gene structure analysis
______________________________________________________________________
Sequence 5: MSTRG.2451.5, from 1 to 3512.
**********************************************************************
Query protein sequence 2 (File: NP_766598.1)
1 MKRAAAKHLI ERYYHQLTEG CGNEACTNEF CASCPTFLRM DNNAAAIKAL ELYKINAKLC
61 DPHPSKKGAS SAYLENSKGA SNNSEIKMNK KEGKDFKDVI YLTEEKVYEI YEFCRESEDY
121 SPLIRVIGRI FSSAEALVLS FRKVKQHTKE ELKSLQEKDE DKDEDEKEKA ACSAAAMEED
181 SEASSSRMGD SSQGDNNVQK LGPDDVTVDI DAIRRVYSSL LANEKLETAF LNALVYLSPN
241 VECDLTYHNV YTRDPNYLNL FIIVMENSNL HSPEYLEMAL PLFCKAMCKL PLEAQGKLIR
301 LWSKYSADQI RRMMETFQQL ITYKVISNEF NSRNLVNDDD AIVAASKCLK MVYYANVVGG
361 DVDTNHNEED DEEPIPESSE LTLQELLGDE RRNKKGPRVD PLETELGVKT LDCRKPLISF
421 EEFINEPLND VLEMDKDYTF FKVETENKFS FMTCPFILNA VTKNLGLYYD NRIRMYSERR
481 ITVLYSLVQG QQLNPYLRLK VRRDHIIDDA LVRLEMIAME NPADLKKQLY VEFEGEQGVD
541 EGGVSKEFFQ LVVEEIFNPD IGMFTYDEAT KLFWFNPSSF ETEGQFTLIG IVLGLAIYNN
601 CILDVHFPMV VYRKLMGKKG TFRDLGDSHP VLYQSLKDLL EYEGSVEDDM MITFQISQTD
661 LFGNPMMYDL KENGDKIPIT NENRKEFVNL YSDYILNKSV EKQFKAFRRG FHMVTNESPL
721 KYLFRPEEIE LLICGSRNLD FQALEETTEY DGGYTRESVV IR-
Predicted gene structure (within gDNA segment 1 to 3512):
Exon 1, 3: 64 (62 n); Protein 745, 762 (18 aa); score: 0.027
MATCH MSTRG.2451.5+ NP_766598.1 0.027 62 0.027 P
PGS_MSTRG.2451.5+_NP_766598.1 (3 64)
Alignment:
GAGCCCTCGC CCGGCAGGGT TGGCGCGCGC TGCCTGTCGG GATACTCGGT CCGCC-CACC 61
E P S P G R V G A R C L S G Y S V R T
| + | . . . + |


























































Figure C.5: Five informative snps located within exon 4.1. Paternal allele specific expres-
sion.
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C.6 Temporal regulation of isoform 4
Table C.3: Mouse tissue information by study
Study Strain Tissue Accession Read count (million)








Temporal hippocampal RNA-seq datasets were extracted from E18, P1, P10 and P30














































Figure D.1: Example schematic of Ube3aY FP embryonic stem cell generation and expan-
sion.
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Table D.1: Composition of Medium






















































Progesterone P8783-1G 20 nM
Putrescence P5780-5G 100 nM













GlutaMAX 35050061 2 mM
B27 17504044 1%










Figure D.2: A model of Topotecan inhibition of topoisomerase I actions.
Table D.2: Shapiro-Wilk Results
Plate Well Treatment PValue N
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Figure D.4: Topotecan induces reactivation of paternal Ube3a allele in ES cell-derived
neurons. A) Confocal image (40X magnification) of Ube3aY FP ES cell-derived neurons
at 2 and 13 days post dissociation (DPD) demonstrating the imprinting of paternal Ube3a.
Nuclei marker TO-PRO-3 (blue), GFP (red), and III Tub (green). B) Confocal image
(40X magnification) of ES cell-derived neurons at 13 DPD with vehicle (water) or Topote-
can (300 nM) treatment demonstrating the reactivation of paternal Ube3a. Nuclei marker
TO-PRO-3 (blue), GFP (green), and III Tub (red).
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Figure D.5: Sample script for plate analysis
184


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    file$Section <- as.character(file$Section)
    well.split <- ldply(strsplit(file$Section, " - "))
    names(well.split) <- c("Well.Letter", "Well.Number")
    new.file <- cbind(well.split, file)
    return(new.file)
}
outdir <- "/PATH/TO/OUTPUT"




for (i in seq_along(files_full)){
    file <- read.csv(files_full[i]);new.file <- split.files(file)
    txt.wells  <- subset(new.file, Well.Number == "2" | Well.Number == "23")
    ntxt.wells <- subset(new.file, Well.Number == "1" | Well.Number == "24")
    wellT.unique <- unique(txt.wells$Section);wellN.unique <- unique(ntxt.well
s$Section)
    par(mfrow = c(2, 5))
    ntxt.test <- sample(wellN.unique, 5)    ## Unseeded
    st_crt.pvalue  <- vector();count_crt <- vector()
    for (j in 1:5){
        crt  <- subset(ntxt.wells, Section == ntxt.test[j])
        if (length(crt$YFPintensity) >= 3){
            st_crt.pvalue  <- c(st_crt.pvalue, shapiro.test(crt$YFPintensity)$
p.value)
        } else {st_crt.pvalue  <- c(st_crt.pvalue, NA)}
        count_crt <- c(count_crt, length(crt$YFPintensity))
        qqnorm(crt$YFPintensity, main = paste0("Q-Q Plot: ",ntxt.test[j]));
        qqline(crt$YFPintensity, col = 2)
    }
    txt.test  <- sample(wellT.unique, 5)    ## Unseeded
    st_topo.pvalue <- vector();count_topo <- vector()
    for (j in 1:5){
        topo <- subset(txt.wells, Section == txt.test[j])
        if (length(topo$YFPintensity) >= 3){
            st_topo.pvalue <- c(st_topo.pvalue, shapiro.test(topo$YFPintensity
)$p.value)
        } else {st_topo.pvalue <- c(st_topo.pvalue, NA)}
        count_topo <- c(count_topo, length(topo$YFPintensity))
        qqnorm(topo$YFPintensity, main = paste0("Q-Q Plot: ",txt.test[j]));
        qqline(topo$YFPintensity, col = 2)
    }
    par(mfrow = c(1,1));st.pvalues <- c(st_crt.pvalue, st_topo.pvalue)
    test.wells <- c(ntxt.test, txt.test);counts <- c(count_crt, count_topo)
    tmp <- seq_along(files_full);plate_number <- paste0("Plate_", tmp[i])




write.table(shapiroWilk, file = paste0(outdir,Sys.Date(),"_ShapiroWilk_Normali
tyTest_pvalues.csv"),sep =",", append=F,row.names=F,col.names=T)
dev.off()








1. Move tails (or ear punches) to 1.5 ml tube that does not leak if necessary.
2. Add 400 Proteinase K mastermix to each tail.
(a) 400 l of NTES, Table E.1
(b) 1 l of Proteinase K
3. Incubate overnight at 50C, constant agitation.
4. Next day, spin down for 5 min at 14,000 rpm.
5. Pour supernatant into new labeled tube.
6. Add 650 l of isopropanol that has been cooled in -20C for > 1 h1.
7. Shake by hand until a precipitate forms.
8. Spin down for > 1 min at 14,000 rpm.
9. Pour supernatant off and set upside-down to dry briefly on a paper towel2.
10. Add 1 ml of 70% EtOH to the tubes.
11. Gently free the pellet from the side of tube with a flick.
12. Set the sample to rock for > 30 min at room temperature3.
1If precipitate does not form immediately, place in -20C for > 2 h.
2Care should be taken when pouring off supernatant so as not to loss DNA at bottom of tube.
3The longer the wash, the cleaner the sample. Rock overnight for best results. For really dirty samples,
70% EtOH can be changed out.
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13. Spin down sample for 1 min at 14,000 rpm.
14. Pour off 70% EtOH and blot dry on paper towel.
15. Set on heat-block with lid open for about 10 min (10 - 15 min) at 37C to 65C.
16. Add purified water (or elution buffer) based on the amount of DNA in the tube and
close lid for overnight incubation4.
KAPA Mouse Genotyping
1. Setup mastermix for DNA extraction reactions.
(a) 22 l of PCR-grade water
(b) 2.5 l of 10X KAPA Express Extract Buffer
(c) 0.5 l of 1 U/l KAPA Express Extract Enzyme
2. Add 25 l/sample in PCR 120 l tubes.
3. Run lysis protocol on PCR machine5.
(a) Lysis step - 75C for 10 min
(b) Enzyme inactivation - 95C for 5 min
4. Centrifuge samples briefly to pellet cellular debris.
5. Dilute DNA extract 10-fold with 10 mM Tris-HCl (pH 8.0 - 8.5)6.
E.1.2 Ube3aY FP Genotyping
Standard
1. Measure DNA with nanodrop before continuing7.
2. For best results, dilute each sample to 50 ng/l.
3. Make up mastermix.
(a) 11.4 l of water
4If uncertain about the amount of water to add, use low amounts like 50 l and adjust after experience.
5KAPA Express Extract will not completely degrade the tissue like Proteinase K, so there will be intact
tissue in the tube after lysis.
6This is necessary to dilute out the salts leftover by lysis.
7For Ube3aY FP Genotyping, 100 ng/l required.
201
(b) 5.0 l of 5X Taq Buffer
(c) 2.5 l of MgCl2
(d) 1.0 l of dNTP
(e) 1.0 l of forward primer
(f) 0.15 l of R1 primer
(g) 0.5 l of R2 primer
(h) 1.25 l of DMSO
(i) 0.2 l of Taq Polymerase
4. Add 23 l of mastermix to each PCR tube.
5. Add 2 l of diluted DNA to each tube.
6. Run PCR protocol.
(a) 1 cycle of 95C for 5 min
(b) 35 cycles of
 95C for 40 s
 54C for 40 s
 72C for 60 s
(c) 1 cycle of 72C for 7 min
(d) Hold at 4C
7. Spin down and store at 4C.
KAPA PCR Reaction
1. Make up master mix.
(a) 7 l of PCR-grade water
(b) 10 l of 2X KAPA2G Fast Genotyping Mix with dye
(c) 1.0 l of forward primer
(d) 0.5 l of R1 primer
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(e) 0.5 l of R2 primer
2. Add 19 l of mastermix to each PCR tube.
3. Add 1 l of diluted DNA to each tube.
4. Run PCR protocol.
(a) 1 cycle of 95C for 3 min
(b) 35 cycles of
 95C for 15 s
 58C for 15 s
 72C for 30 s
(c) 1 cycle of 72C for 2 min
(d) Hold at 4C
5. Spin down and store at 4C.
E.1.3 Gel Electrophoresis
1. Make 1 to 1.5% agarose gel.
(a) Measure out 1 to 1.5 g of agarose
(b) Pour agarose powder into glass flask
(c) Add 100 ml of 1xTAE buffer to glass flask, Table E.1
(d) Microwave until agarose completely dissolves8
(e) Let agarose solution cool down for 10 min9
(f) Add 5 l of ethidium bromide (EtBr) or other DNA imaging solution10.
2. Setup gel tray if needed.
3. Pour the agarose solution into a gel tray with desired well comb in place and let
solidify for 10 to 15 min.
8Be careful that it does not boil over. It is a good idea to microwave for 30 s and stop and swirl, then
continue to boil.
9Use running water to speed the process up if desired.
10EtBr is a known mutagen, so use with caution (i.e. always wear nitrile gloves when working with it).
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4. Place gel into gel electrophoresis unit with 1xTAE until gel is completely covered.
5. Load DNA molecular weight ladder into first lane of the gel and PCR samples after
it.
6. Run at 100V for > 1 h.
7. Use UV light to visualize DNA fragments.
+/YFP 1 2 3 5 6 8 9 10 11 +/+ H2O
Figure E.1: Example of standard Ube3aY FP Genotyping using Ube3a+=Y FP ES cells gel
image.
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Table E.1: Media composition
Media Components Amount
NTES Buffer Sterile H2O 315 ml
SDS 1% (50 ml of 10%)
NaCl 0.1 M (10 ml of 5 M)
EDTA 0.1 M (100 ml of 0.5 M)
Tris 0.05 M, pH 8 (25 ml of 0.5 M)
50X stock TAE Tris-base 242.2 g
Glacial acetic acid 57.1 ml
EDTA 0.5 M, pH 8, 100 ml
Sterile H2O up to 1 L
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E.2 High-throughput Image Analysis
E.2.1 Image Processing
GFP only
1. Launch Developer Toolbox




4. Select protocol: GFP only uses YFP Only v1
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5. Within the protocol, targets are pre-processed using Denoising (gradient) at kernel
size = 3.
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6. Within the protocol, targets are segmented via
 Nuclear Segmentation
 Minimum target area (237 pixel)




7. Within the protocol, post-processing uses the following
 Watershed clump breaking
 Sieve (binary)
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8. Within the protocol, targets can be directly measured using GFP channel.
(a) Density Levels of target




Nuclei-Overlap image processing method uses the same protocol for GFP channel; how-
ever adds the Nuclei channel as well.
1. Process GFP channel
(a) Pre-processing steps for GFP channel as above.
(b) Segmentation for GFP channel as above.
(c) Post-processing steps for GFP channel as above.
(d) Collect Median Intensity (Density Levels) for GFP channel.
2. Process Nuclei channel
(a) Pre-processing steps for Nuclei channel - Denoising, kernel size = 3.
(b) Segmentation for Nuclei channel - optimize for maximum nuclei targeting.
(c) Post-processing steps for Nuclei channel - Watershed & Sieve.
(d) Collect cell count (optional).
3. Generate overlapping mask
(a) Create linking target
(b) Nuclei target 70% overlapping of GFP target
4. Collect data, Median Density & Area from GFP channel
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NeuN-Overlap
NeuN-Overlap image processing method uses the same protocol for Nuclei-Overlap method;
however with additional NeuN channel.
1. Process GFP channel
(a) Pre-processing steps for GFP channel as above.
(b) Segmentation for GFP channel as above.
(c) Post-processing steps for GFP channel as above.
(d) Collect Median Intensity (Density Levels) for GFP channel.
2. Process Nuclei channel
(a) Pre-processing steps for Nuclei channel - Denoising, kernel size = 3.
(b) Segmentation for Nuclei channel - optimize for maximum nuclei targeting.
(c) Post-processing steps for Nuclei channel - Watershed & Sieve.
(d) Collect cell count (optional).
3. Process NeuN channel
(a) Pre-processing steps for NeuN channel - Denoising, kernel size = 3.
(b) Segmentation for NeuN channel - optimized for maximum target selection.
(c) Post-processing steps for NeuN channel - Watershed & Sieve.
(d) Collect cell count (optional).
4. Generate overlapping mask
(a) Create linking target
(b) Nuclei target 70% overlapping of NeuN target
(c) Use generated mask to measure on GFP channel.
5. Collect data, Median Density & Area from GFP channel
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E.2.2 R programming analysis
GE Developer will produce text files (csv) that can be imported into programs such as R11.
1. Edit text files by removing the top two lines (either by command-line or by hand)
for easy of R programming import.
11For Excel version 2016, data is truncated and should not be opened in this type of program.
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2. The following R script was developed for high-throughput data processing.
 Well mean
 Well median






3. The R script outputs csv file for down-stream data analysis.
4. Another R script was developed for Well separation for by Well analysis in down-
stream data analysis (csv).
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5. UpperQ (Upper quantile analysis) R script separates out the 75-99 percentile targets
per plate.
6. Calculates well statistics and outputs csv file.
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E.2.3 Shiny App
The app can be found here:
https://kj-benjamin90.shinyapps.io/angelman-hts-app/.
There are four main files and/or directories including: 1) ui.R, 2) server.R, 3) boot-
strap.css, and 4) training datasets. The bootstrap.css file is used for webpage style.
The training datasets are used to generate simulated plate data.
The app is broken into three major functions. The first checks that the text files have
been edited. It throws a warning if it has not been (“No”), and if the files have been
(“Yes”) then prompts the user to upload the files to be analyzed. The user than has the
option to check quality control of the plates be comparing topotecan treated wells with
vehicle wells, or to directly download the processed data for downstream analysis.
Quality control of the plates is the second major function. The app looks at an unpaired
one-sided Student’s T Test (ttest), the z factor (Zfactor), and the strictly standardized mean
difference (SSMD). This data can also be downloaded at the click of a button.
The final function is the generation of simulated plate data. This function simulates 9
plate randomly with each download. These files can than be used without outside manip-
ulation for plate analysis and quality control.










p("This app is for downstream analysis of GE Developer
image analysis using the NeuN Overplay protocol, which
outputs median YFP intensity in column 3. It does the
following: 1) generate output summary statistics (mean,
standard deviation, median, and cell count) for each well
per plate imported; 2) quality control data assuming
positive (col 2 & 23) and negative controls (col 1 & 24)
in a 384 well plate."))),
column(4, align = "center",
textInput("drug", label = h4("What is the name of drug
library?"),
value = "Enter library name..."),
numericInput("plates", "Please enter the initial plate
number: ",
1, min = 1, max = 100),

















condition = "input.simulation == true",
downloadButton("testDownload","Download"),
helpText("Note: Data is randomly generated with each
download. The top 2 lines do not need to












h5("Left side of Plate", align = "center"),
tableOutput("left")),
column(4,
h5("Entire Plate", align = "center"),
tableOutput("all")),
column(4,

















z <- 1 - ((3*(sd(data1, na.rm = T) + sd(data2, na.rm = T))) /






beta <- (median(data1, na.rm = T) - median(data2, na.rm = T)) /










title = "Important message",
















for (i in seq_len(nrow(inFile))){






for (j in seq_along(unique.wells)){
wells <- subset(lst, Section==unique.wells[j])
well.mean <- mean(wells[,3], na.rm = TRUE)
well.sd <- sd(wells[,3], na.rm = TRUE)
well.med <- median(wells[,3], na.rm = TRUE)
cell.count <- length(wells[,3])
out.mean <- c(out.mean, well.mean)
out.sd <- c(out.sd, well.sd)
out.med <- c(out.med, well.med)
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out.count <- c(out.count, cell.count)
}
plate.name <- rep(paste0("Plate_", tmp),
length(unique.wells))


















dlist1 <- plyr::dlply(leftData, "PlateID",




for (k in plateNames1){
file <- dlist1[[k]]
file$Well <- as.character(file$Well)
well.split <- ldply(strsplit(file$Well, " - "))
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names(well.split) <- c("Well.Letter", "Well.Number")
new.file <- cbind(well.split, file)
txt <- subset(new.file, Well.Number == "2",
select = Median)
ntxt <- subset(new.file, Well.Number == "1",
select = Median)
stat1 <- c(stat1, t.test(txt,ntxt,
alternative="greater")$p.value)
stat2 <- c(stat2, zfactor(txt,ntxt))
stat3 <- c(stat3, ssmd(txt,ntxt))
}
pvalues <- data.frame(ID = plateNames1, Ttest = stat1,









dlist2 <- plyr::dlply(allData, "PlateID",










well.split <- ldply(strsplit(file$Well, " - "))
names(well.split) <- c("Well.Letter", "Well.Number")
new.file <- cbind(file, well.split)
txt <- subset(new.file, Well.Number == "2" |
Well.Number == "23",
select = Median)
ntxt <- subset(new.file, Well.Number == "1" |
Well.Number == "24",
select = Median)
stat1 <- c(stat1, t.test(txt, ntxt,
alternative="greater")$p.value)
stat2 <- c(stat2, zfactor(txt, ntxt))
stat3 <- c(stat3, ssmd(txt, ntxt))
}
pvalues <- data.frame(ID = plateNames2, Ttest = stat1,









dlist1 <- plyr::dlply(rightData, "PlateID",








well.split <- ldply(strsplit(file$Well, " - "))
names(well.split) <- c("Well.Letter", "Well.Number")
new.file <- cbind(well.split, file)
txt <- subset(new.file, Well.Number == "23",
select = Median)
ntxt <- subset(new.file, Well.Number == "24",
select = Median)
stat1 <- c(stat1, t.test(txt, ntxt,
alternative="greater")$p.value)
stat2 <- c(stat2, zfactor(txt, ntxt))
stat3 <- c(stat3, ssmd(txt, ntxt))
}
pvalues <- data.frame(ID = plateNames3, Ttest = stat1,


















dlist <- plyr::dlply(tempData, "PlateID",




































tempdir(), full.names = TRUE)))
tempdir2 <- tempdir()
write.csv(x = left(),








file = paste0(tempdir2, "/",
"Plate_right-side", ".csv"),
row.names = FALSE)















for (k in seq_along(files_full)){
files <- read.csv(files_full[k])
files$Section <- as.character(files$Section)
well.split <- ldply(strsplit(files$Section, " - "))
names(well.split) <- c("Well.Letter", "Well.Number")
new.file <- cbind(well.split, files)
txt.left <- subset(new.file, Well.Number == "2",
select = YFPintensity)
ntxt.left <- subset(new.file, Well.Number == "1",
select = YFPintensity)
txt.right <- subset(new.file, Well.Number == "23",
select = YFPintensity)
ntxt.right <- subset(new.file, Well.Number == "24",
select = YFPintensity)
rest <- subset(new.file, Well.Number != "1" &
Well.Number != "2" &
Well.Number != "23" &
Well.Number != "24",
select = c(Section, YFPintensity))
## This returns several data.frames with $YFPintensity for values.
plate <- data.frame()
## Column 1 (ntxt.left)
size1 <- sample(5:400, 16)
row1 <- vector()
for (j in 1:16){
yfp1 <- sample(ntxt.left$YFPintensity,
size = size1[j], replace = TRUE)
well1 <- rep(paste(LETTERS[j], "-", "1", sep=" "),
size1[j])
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df.tmp1 <- cbind(well1, 1:size1[j], yfp1)
row1 <- rbind(row1, df.tmp1)
}
plate <- row1
## Column 2 (txt.left)
size2 <- sample(5:400, 16)
row2 <- vector()
for (j in 1:16){
yfp2 <- sample(txt.left$YFPintensity,
size = size2[j], replace = TRUE)
well2 <- rep(paste(LETTERS[j], "-", "2", sep=" "),
size2[j])
df.tmp2 <- cbind(well2, 1:size2[j], yfp2)
row2 <- rbind(row2, df.tmp2)
}
plate <- rbind(plate, row2)
## Columns 3 to 22 (rest)
for (i in 3:22){
size <- sample(5:400, 16)
num <- i
row <- vector()
for (j in 1:16){
yfp <- sample(rest$YFPintensity,
size = size[j], replace = TRUE)
well <- rep(paste(LETTERS[j], "-", num, sep=" "),
size[j])
df.tmp <- cbind(well, 1:size[j], yfp)
row <- rbind(row, df.tmp)
}
plate <- rbind(plate, row)
}
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## Column 23 (txt.right)
size23 <- sample(5:400, 16)
row23 <- vector()
for (j in 1:16){
yfp23 <- sample(txt.right$YFPintensity,
size = size23[j], replace = TRUE)
well23 <- rep(paste(LETTERS[j],"-","23",sep=" "),
size23[j])
df.tmp23 <- cbind(well23, 1:size23[j], yfp23)
row23 <- rbind(row23, df.tmp23)
}
plate <- rbind(plate, row23)
## Column 24 (ntxt.right)
size24 <- sample(5:400, 16)
row24 <- vector()
for (j in 1:16){
yfp24 <- sample(ntxt.right$YFPintensity,
size = size24[j], replace = TRUE)
well24 <- rep(paste(LETTERS[j],"-","24",sep=" "),
size24[j])
df.tmp24 <- cbind(well24, 1:size24[j], yfp24)
row24 <- rbind(row24, df.tmp24)
}
plate <- rbind(plate, row24)
plate.data <- as.data.frame(plate)
names(plate.data) <- c("Section", "Zipget",
"YFPintensity")
tmp <- seq_along(files_full)
plate_number <- paste0("Plate_", tmp[k], "_")
write.csv(plate.data,












E.3.1 Fixation - Cell Culture
1. Wash media from slides gently with 1xPBS, twice.
2. Remove 1xPBS and add 4% PAF/4% Sucrose to each coverslip12.
3. Agitate for 10 min at room temperature.
4. Rinse coverslips gently twice with 1xPBS.
5. Add 1xPBS to wells and cover with aluminum foil.
6. Store at 4C.
E.3.2 Staining - Cell Culture
1. Make up 5% goat serum fresh in 0.3% Triton X-100 in 1xPBS.
2. Transfer coverslips to new plate, blotting off excess PBS.
3. Add 5% goat serum fresh to coverslips and incubate at room temperature with slight
agitation for 1 h.
4. Prepare primary antibodies using 5% goat serum.
 anti-GFP diluted at 1:1000 (anti-rabbit)
 anti-NeuN diluted at 1:250 (anti-mouse)
5. Replace 5% blocking solution (goat serum) with primary antibodies13.
6. Incubate primary antibodies for 1 h at room temperature with slight agitation.
7. Wash three times coverslips with 0.1% Tween20 in 1xPBS; 10 min at room temper-
ature with slight agitation.
8. Prepare secondary antibodies using 5% goat serum during last wash at 1:200 dilu-
tion.
9. Replace last wash with secondary antibody solution.
12Use freshly made fixation solution ( 7 days).
13Be careful of bubbles.
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10. Incubate secondary antibodies for 1 h at room temperature with slight agitation cov-
ered with aluminum foil14.
11. Wash twice with 0.1% Tween20 in 1xPBS for 10 min each at room temperature with
slight agitation.
12. Replace wash with TO-PRO-3 (1:1000) in 0.1% Tween20 in 1xPBS for 10 min at
room temperature with slight agitation.
13. Wash coverslips with 0.1% Tween20 in 1xPBS for 10 min with slight agitation at
room temperature.
14. Store at 4C until ready for imaging.
14Aluminum foil and dark conditions should be used for the remainder of staining protocol.
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E.4 Rapid Amplification of cDNA Ends (3’)
The following uses the 3’ RACE System (Cat. No. 18373019) from ThermoFisher Scien-
tific. Everything but RNA, Taq Polymerase, and gene specific primers provided within the
kit, as such developing gene specific primers is the first step for 3’ RACE.
E.4.1 First-Strand cDNA Synthesis
1. Combine DEPC-treated water and 2.5 - 5 g of total RNA to a final volume of 11 l
to a PCR tube.
2. Add 1 l of 10 M AP solution and mix with a flick.
3. Spin down briefly and heat mixture in PCR thermocycler.
(a) 70C for 10 min
(b) 4C for > 1 min
4. Spin down briefly and add the following
(a) 2 l of 10X PCR buffer
(b) 2 l of 25 mM MgCl2
(c) 1 l of 10 mM dNTP mix
(d) 2 l of 0.1 M DTT
5. Mix gently and spin down before placing on PCR thermocycler held at 42C.
6. Equilibrate sample for 2 - 5 min.
7. Add 1 l of SuperScriptTM II RT and perform the following
(a) 42C for 50 min
(b) 70C for 15 min
(c) Hold at 4C
8. Spin down and add 1 l of RNase H.
9. Mix and spin down before incubating for 20 min at 37C.
10. Store at -20C or proceed to Amplification of Target cDNA.
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E.4.2 Amplification of Target cDNA
1. Combine the following in a PCR tube.
(a) 14.6 l of DEPC-treated water
(b) 2 l of 10X PCR buffer
(c) 1.2 l of MgCl2
(d) 0.4 l of Gene Specific forward primer
(e) 0.4 l of AUAP (abridged universal amplification primer) reverse primer
(f) 0.4 l of dNTP
(g) 0.8 l of cDNA (from First Strand Synthesis)
(h) 0.2 l of Taq Polymerase
2. Place on thermocycler15
(a) 1 cycle of 94C for 3 min
(b) 35 cycles of
 94C for 30 s
 (gradient) 65C for 60 s
 72C for 60 s
(c) 1 cycle of 72C for 5 min
(d) Hold at 4C
3. Preform second amplification in new PCR tube.
(a) 36.5 l of DEPC-treated water
(b) 5.0 l of 10X PCR buffer
(c) 3.0 l of MgCl2
(d) 1.0 l of Nested-Gene Specific forward primer
(e) 1.0 l of AUAP reverse primer
15For optimal amplification a gradient PCR should be run.
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(f) 1.0 l of dNTP
(g) 2.0 l of cDNA (from first amplification - optimized)
(h) 0.5 l of Taq Polymerase
4. Run at optimal melting temperature on thermocycler.
(a) 1 cycle of 94C for 3 min
(b) 35 cycles of
 94C for 30 s
 65C for 60 s
 72C for 60 s
(c) 1 cycle of 72C for 5 min
(d) Hold at 4C
5. Place 4 l of PCR reaction into new tube and store at 4C.
E.4.3 Electroporation Cloning & Insert Verification
1. Run PCR product (46 l) out on 1.5% agarose gel (100V, > 1 h).
2. Cut out amplified band(s) for gel purification.
3. Use Gel Purification kit to purify PCR products.
4. Ligate PCR products into TOPO TA vector.
(a) Using TOPO TA Cloning kit, add the following
 0.5 l of 2.1 TOPO Vector
 0.5 l of RNase-free water
 1.0 l of salt solution
 4.0 l of PCR product (direct, and gel purified in different tubes)
(b) Incubate for 30 min at room temperature
(c) Dilute ligation reactions 1=4 with RNase-free water (18 l of H2O)
(d) Add 2 l to electro-competent cells for electroporation
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(e) Add mixature to curvettes for electroporation
(f) After electroporation add SOC media to cells
(g) Shake at 37C for 1 h
(h) Plate on Ampicilin+ and X-gal treated Luria broth (LB)-agar plates
 50 l plate
 High concentration plate
(i) Culture overnight at 37C
5. Perform plasmid DNA purification and measure DNA with nanodrop.
6. Verify insertion with restriction enzyme (RE) digestion (EcoRI-HF, NEB).
(a) Combine the following in PCR tube
 1 g of plasmid DNA
 5 l of CutSmart Buffer
 1 l of RE
 Water to final volume of 50 l
(b) On thermocycle
 37C for 40 min
 65C for 20 min
 Hold at 4C
(c) Run out on 1 - 1.5% agarose gel (100V,  1 h)
(d) Image gel for insert verification
7. Send DNA for sequencing.
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E.5 Reverse-transcription PCR/qPCR
The SuperScript R IV First-Strand Synthesis System from ThermoFisher Scientific is used
for the following protocol.
E.5.1 First-Strand Synthesis
1. Using DNase treated RNA (2-5 g total RNA), combine with 1 l of 50 M Oligo
d(T)20 primer, 1 l of 10 mM dNTP mix, and DEPC-treated water to final volume
of 13 l in PCR tube.
2. Mix gently and spin down before heating on thermocycler at 65C for 5 min.
3. Incubate at 4C for  1 min.
4. Make a mastermix of the following components
(a) 4 l of 5X SSIV Buffer
(b) 1 l of 100 mM DTT
(c) 1 l of Ribonuclease Inhibitor
(d) 1 l of either SuperScript R IV Reverse Transcriptase or DEPC-treated water
5. Add 7 l of mastermix to primer annealed RNA.
6. Incubate mixture for 10 min at 50C followed by 10 min at 80C.
7. (optional) Add 1 l of RNase H to samples and incubate for 20 min at 37C.
8. Store cDNA at -20C.
For reverse-transcription PCR, dilute cDNA and proceed to running PCR reactions.
E.5.2 SYBR Green qPCR
1. Design qPCR primers and verify size and single band with PCR amplification.
2. Setup qPCR plate layout.
3. Dilute enough cDNA at 1:4 for experiment.
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4. Create 1:4 serial dilution standards ( 5) of pooled cDNA16.
5. Dilute samples 1:5 (1:20 dilution from original cDNA).
6. Make mastermix for each primer set
(a) 5 l of 2X SYBR Green Buffer
(b) 500 nM forward primer (final)
(c) 500 nM reverse primer (final)
(d) DEPC-treated water to final volume of 8 l
7. Add mastermix to plate following layout.
8. Add samples to plate.
9. Seal off plate, vortex, and spin down.
10. Run qPCR reaction
(a) 1 cycle of 50C for 2 min
(b) 1 cycle of 95C for 10 min
(c) 40 cycles of
 95C for 15 s
 60C for 60 s
(d) Dissociation Curve
 95C for 15 s
 60C for 20 s
 72C for 15 s
11. Analysis data.
16Recommend using 4 technical replicas for experimentation.
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E.6 RNA Extraction
For all protocols, work in laminar flow-hood if possible with work area and pipettes
cleaned with RNA-zap if no RNA only pipettes designated. Additionally, all solutions
not provided by the kit should be made with DEPC-treated water (i.e. sodium acetate and
75% EtOH).
E.6.1 Tissue RNA isolation
The following is a TRIzol method for RNA extraction and isolation.
TRIzol extraction
1. Set centrifuge for 4C.
2. Prepare Sonicator for RNA extraction by cleaning with RNase-Zap and DEPC-
treated water.
3. Homogenize samples (held on ice) in 1 ml of TRIzol for 60 s17.
4. Incubate at room temperature for 5 min.
5. Add 200 l of Chloroform and shake by hand vigorously for 15 s.
6. Incubate for 2 - 3 min at room temperature.
7. Centrifuge (12; 000 g) for 15 min at 4C18.
8. Transfer aqueous phase to new RNase-free tube.
9. Add 500 l of isopropanol and incubate for 10 min at room temperature.
10. Centrifuge (12; 000 g) for 10 min at room temperature.
11. Aspirate and discard supernatant and resuspend pellet in 1 ml of 75% EtOH.
12. Vortex to mix and centrifuge at (7; 500 g) for 5 min at 4C.
13. Briefly dry RNA pellet before adding at least 100 l of DEPC-treated water.
14. Incubate for 10 min at 60C.
17Clean Sonicator after every use with RNase-Zap and DEPC-treated water.
18RNA will be in colorless upper phase.
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15. Store at -80C.
RNA clean-up & concentration19
1. Add 1
10
volume of sodium acetate (i.e. 10 l from above extraction) to sample.
2. Add 1 volume of isopropanol to sample.
3. Incubate overnight at -20C.
4. Centrifuge for 15 min at 15; 000 g and discard supernatant carefully.
5. Add 1 ml of 70% EtOH and centrifuge for 2 min at 20; 000 g.
6. Aspirate supernatant and dry pellet.
7. Re-suspend with RNase-free water.
E.6.2 Cell culture RNA isolation
The following protocol is for a monolayer of cells ( 5 106) using the PureLink R RNA
Mini Kit.
1. Prepare lysis buffer by adding 2-mercaptoethanol (ME) to Lysis Buffer (10 l per
1 ml of Lysis solution).
2. Rinse cells gently twice with 1xPBS.
3. Add 300 l of prepared lysis buffer to plated cells.
4. Incubate at room temperature for 3 - 5 min with back and forth motion.
5. Pipette up and down ten times to break up cells.
6. Transfer lysate to new RNase-free tube.
7. Add 1 volume of 70% EtOH to each cell lysate.
8. Vortex until no precipitate is visible.
9. Transfer up to 700 l of sample into spin cartridge.
10. Centrifuge for 30 s at 12; 000 g and discard flow-through20.
19There are kits that can do this as well.
20The following centrifuge are done at room temperature.
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11. Repeat until the entire sample has been processed.
12. Add 700 l of Wash Buffer I to spin cartridge.
13. Centrifuge for 30 s at 12; 000 g.
14. Discard flow-through and collection tube. Place spin cartridge in new collection
tube.
15. Add 500 l of Wash Buffer II and centrifuge for 30 s at 12; 000  g. Discard flow-
through and repeat wash.
16. Centrifuge spin cartridge at 12; 000 g for 90 s to dry membrane.
17. Discard collection tube and insert spin cartridge into recovery tube.
18. Add 30 l of RNase-free water to center of spin cartridge and incubate for 1 min at
room temperature.
19. Centrifuge spin cartridge at 12; 000 g for 2 min.
20. Store purified RNA at -80C.
E.6.3 Cytoplasm & nuclear cell RNA isolation
The following protocol is from the Ambion R PARISTM Kit for RNA extraction.
1. Prepare reagents and setup equipment.
(a) Set heat block to 95C
(b) Set centrifuge to 4C
(c) Add ME to 2X Lysis Buffer21
(d) Add 100% EtOH to 2/3 Wash Buffer22
2. Place Cell Fractionation Buffer on ice before use.
3. Allow 2X Lysis Buffer and Wash Solution 1 to equilibrate to room temperature.
4. Heat an aliquot of Elution Solution to 95C on heat block.
5. Rinse monolayer of cells ( 10 106) with 1xPBS.
21Only add for first time use.
22Only add for first time use.
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6. Add 250 l of Cell Fractionation Buffer to each well23.
7. Incubate at room temperature for 5 - 10 min with back and forth motion, or until
cells completely detached from plate.
8. Transfer to RNase-free tube and incubate on ice for 10 min.
9. Centrifuge samples at 4C for 5 min at 500 g.
10. Carefully transfer supernatant to new RNase-free tube and place on ice. This is the
cytoplasmic fraction.
11. Add 200 l of Cell Fractionation Buffer to pelleted nuclear fraction, and gently
re-suspend pellet.
12. Spin down at 4C for 1 min, 500 g.
13. Aspirate and discard supernatant.
14. Add 1 volume equal to cytoplasmic volume of Cell Fractionation Buffer.
15. Vortex vigorously to lyse nuclei, then place on ice.
16. Add 1:1 2X Lysis Buffer to cytoplasmic and nuclear fractions and invert tubes sev-
eral time to mix well.
17. (optional) Cellular debris removal24
 Pass lysate through syringe needle several times to reduce viscosity and remove
debris
 Spin down and place supernatant into new RNase-free tube
18. Add 1 volume of 100% EtOH to mixture25 and invert several times.
19. Add  700 l of the sample to the filter cartridge.
20. Centrifuge for 30 s (12; 000 g) and discard flow-through.
21. Repeat until all the sample as been passed through the filter.
22. Add 700 l of Wash Solution 1 to column.
23Assuming 6-well plate
24If there is any debris or the samples are too viscous, then they will not pass through the filter cartridges.
25This is the volume before Lysis Buffer added.
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23. Centrifuge for 30 s (12; 000 g) and discard flow-through.
24. Add 500 l of Wash Solution 2/3 to column.
25. Centrifuge for 30 s (12; 000 g) and discard flow-through. Repeat wash once.
26. Place filter cartridge into new collection tube and add 40 - 60 l of Elution Buffer.
27. Centrifuge for 30 s (12; 000 g).
28. Add 10 - 60 l of Elution Buffer to filter cartridge and centrifuge for 30 s (12; 000
g).
29. Store purified RNA at -80C.
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E.7 RNA-seq Analysis
All work performed on Centos 7: Linux, kernal release: 3.10.0-514.6.1.el7.x86_64,
on 64-bit system. The computer has an AMD FX(tm)-8350 Eight-Core Processor, 32G of
RAM, 4.6T of working disk space with an additional 2T of backup disk space.26
E.7.1 Software installation
Tools used in this dissertation include the following: FastQC, Trimmomatics, HISAT2,
SAMtools, StringTie, Gffcompare, Gffread27, BEDtools, BCFtools, GENESEQER, IGV,
Python, R, ballgown, edgeR, and Rsubread.28 I recommend installing most of these soft-
wares locally and adding to PATH, as some of them may have library issues that can mess
with the system.











26This is a home built computer.
27This is part of Cufflinks, but can be downloaded separately.
28If working on a cluster, then you should check to see what software they have. If something is not
present, put in a request. Additionally, do not expect to use the latest updates if working on a cluster.
29Version 2.0.4 of HISAT2 is not the lastest.
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cd ~/rna-seq/tools/












#download with wget (Trimmomatic-0.36.zip)
unzip Trimmomatic-0.36.zip
mkdir -p ~/rna-seq/refs/adapters



























First check to see if R and Python are already installed with which R and which
python. If they are there, then R will often prompt user to update to latest version when
in application, which can be done as root. Note of caution: Python 2 is not the same
as Python 3, so if you are using MISO and have Python 3 installed, then you’ll need to
download Python 2 for it to work as MISO was built with Python 2.
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sudo yum install R.x86_64 -y
sudo yum install python2-pip.noarch python34u-pip.noarch -y
Note: Installing pip for python will also install python as a dependency.
Bioconductor & Packages
This can be done as a local install or global with root access. If you have root access





























The export PATH should be all one line. The indentation is for viewing in this
dissertation. Additionally, if you don’t have emacs, any editor will can be used. Further-
more, if you don’t already have git downloaded you can just use wget for everything.
E.7.2 Reference genomes and annotation
To get everything at once, Illumina’s iGenome can be used, but there will need to be
some cleaning up of unnecessary files to save disk space.













Copy over only Sequence and Annotation files to fasta and annotation directories:
Whole genome fasta, individual chromosome fasta, and current annotation directory. Re-
move the rest with rm -rf. gzip all fasta files that will not be used to save disk space
and remove TAR files.
Once the fasta files are downloaded, index the file you plan to use for alignment with
SAMtools.
samtools faidx chr15.fa




hisat2_extract_splice_sites.py ../annotation/Genes/gene.gtf > \
./splice-exons/splicesites.hg19.tsv
hisat2_extract_exons.py ../annotation/Genes/gene.gtf > \
./splice-exons/exons.hg19.tsv





hisat2_extract_splice_sites.py ../annotation/Genes/gene.gtf > \
./splice-exons/splicesites.mm9.tsv
hisat2_extract_exons.py ../annotation/Genes/gene.gtf > \
./splice-exons/exons.mm9.tsv




This can be done in one of two ways. In a bash script with all of the locations listed,



























fastqc -t 8 *fastq.gz -o ./fastqc-report




FastQC functions to provide a way to view quality of raw sequence data working with
BAM, SAM, or fastq files it exports data as pdfs (zipped) and HTML for easy viewing in
web browser. It can be run interactively with it’s JAVA online function, or as I use it in the
above section offline as a part of a large-scale pipeline. To view the html files:
cd $RNA_HOME/datasets/human/hpa/reads/fastqc-report/
firefox *.html
Regardless of the quality, adapter sequences should be trimmed from the raw sequence.
Trimmomatics









for i in {432,455,477}
do




ILLUMINACLIP:$adapter_file:2:30:10 LEADING:3 TRAILING:3 MINLEN:25
done
mv -v *se* ./SE
For single-end reads use the following:
java -jar $trim/trimmomatic-0.36.jar SE -threads 8 \
$reads/filename.fastq.gz filename_trimmo.fastq.gz \
ILLUMINACLIP:$adapter_file:2:30:10 LEADING:3 TRAILING:3 MINLEN:25
Here you can look at the quality again. fastqc -t 8 *fastq.gz. Make sure
if you use the -o option for FastQC that there is already a directory with that filename.
Otherwise, it will not work.
E.7.6 Alignment with HISAT2
HISAT2 [152] is a fast and sensititve alignment program for mapping next-gen se-
quencing reads from the same producers of TopHat2. Moreover, this is the improvement
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on TopHat2. As there is a manual page man hisat2, I will add only a few of the impor-
tant options below:
1. Main options
(a) -x: Location of indexes (.ht2)
(b) -1/-2: Read 1 and Read 2 for paired-end
(c) -U: Unpaired reads (single-end)
(d) --sra-acc: SRA file format
2. Input options
(a) -q: fastq reads (default)
(b) -f: fasta reads
3. Spliced alignment options
(a) --min-intronlen: Default 20
(b) --max-intronlen: Default 500000
(c) --novel-splicesite-outfile: location for output
(d) --rna-strandness: FR or RF for paired-end (RF for TruSeq)
(e) --dta: alignments for StringTie analysis
(f) --dta-cufflinks: alignments for Cufflinks analysis










for i in {432,455,477}
do




samtools view -@ 8 -Shb | \




For viewing in IGV and a few other downstream programs, the sorted BAM files need
to be merged by tissue and indexed.





By only indexing the merged files, this saves disk space. If disk space is not an issues,
then each sorted BAM can be indexed within the hisat2 for-loop by adding:
samtools index $output_SAM/ERR315${i}.chr15.sorted.bam
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E.7.7 Annotations with StringTie
StringTie [151, 154]: Transcript assembly and quantification for RNA-Seq, produced
by Johns Hopkins University, Center for Computational Biology like Cufflinks.
Table E.2: StringTie Options
Flag Options Description
-h Prints help message and exits.
-v Verbose mode, prints bundle processing details.
-o <path> Set name for output GTF file.
-p <int> Number of processing threads to use for assembly.
-G <gff> Reference annotation file (gtf or gff3 format).
-l <label> Sets label as prefix for the output transcripts.
-C <gtf> Output file with names of fully covered transcripts. (-G)
-B Output of Ballgown input table with coverage data for transcripts. (-G)
-b <path> File path for Ballgown output. (-G)
-e Only assemble reads that match reference. (-G, -B/-b)






for i in {432,455,477}
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do
echo "Running sample: ERR315"$i




ls -1 unstranded/*/transcripts.chr15.gtf > \
unstranded/mergelist_gtf.txt
The next step is to use stringtie --merge (E.3) with all of the predicted transcriptomes
to make one final transcriptome annotation for downstream analysis.
Table E.3: StringTie Merge Options
Flag Options Description
-G Reference annotation to include in the merging (gtf/gff3).
-o <path> Set name for output GTF file.
-m <int> Minimum input transcript length (default: 50).
-c <int> Minimum input transcript coverage (default: 0).
-F <int> Minimum input transcript FPKM (default: 0).
-T <int> Minimum input transcript TPM (default: 0).
-f <float> Minimum isoform fraction (default: 0.01).
-i Keep merged transcripts with retained introns (default: no).
-l <label> Name prefix for output transcripts.









stringtie --merge -p 8 -G $annot \
-o $outputDIR/stringtie_merged.0.gtf $mergeLIST
stringtie --merge -p 8 -f 0.05 -G $annot \
-o $outputDIR/stringtie_merged.1.gtf $mergeLIST
stringtie --merge -p 8 -F 5 -G $annot \
-o $outputDIR/stringtie_merged.2.gtf $mergeLIST
stringtie --merge -p 8 -f 0.05 -F 5 -G $annot \
-o $outputDIR/stringtie_merged.3.gtf $mergeLIST
stringtie --merge -p 8 -F 10 -G $annot \
-o $outputDIR/stringtie_merged.4.gtf $mergeLIST
stringtie --merge -p 8 -F 5 -T 10 -G $annot \
-o $outputDIR/stringtie_merged.5.gtf $mergeLIST
Once I have the correct parameters, I rename the file (mv -v) so that I know which is
the annotation file to use.
E.7.8 Working with IGV
1. Lauch IGV with igv.sh
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2. Load Genome with the drop down menu
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3. Load Genome annotation: File! Load from File...
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4. Zoom into region of interest by
(a) changing chromosomes:
(b) zooming in with buttons:
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5. Load a sorted BAM file similar to loading a genome annotation
6. Show splicing junctions
7. Open a Sashimi plot
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8. Save an image by right-clicking on screen
9. Use a tool with Tools
(a) BEDtools options
(b) BLAT options (no file input, but direct sequence)
(c) And more...
BLAT
Generating BED files from Sanger sequence data like 3’RACE involves first using the
tool BLAT within IGV and second exporting (right-click) it as a BED file. Once that has
been done, file manipulation can be done with the following commands assuming all BED
files have filename: iso*. Use man on any Bash function (i.e. paste) to read about it in
more detail.
paste -s -d "\n" iso* > isoforms.hg19.bed
sortBed -i isoforms.hg19.bed > isoforms.hg19.sorted.bed
bedtools merge -i isoforms.hg19.sorted.bed > isoforms.hg19_merged.bed
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Visualizing SNP data in IGV
awk ’$1 == "7" { print $2 }’ snp.file.tsv > snps.tsv
grep -f snps.tsv hippo.flt.vcf > informative.snps.vcf
In emacs copy over the header from the hippo.flt.vcf, so that I can view in IGV.
Otherwise, cannot view this file in IGV.
E.7.9 SNP analysis
SNP information for region of interest downloaded from the Mouse Genomes Project
- Query SNPs from Wellcome Trust Sanger Institute. To call variants, preform the follow-
ing:
samtools mpileup -ugf chr7.fa -r chr7:region of interest \
file1.sorted.bam file2.sorted.bam ... | \
bcftools call -c - > var.raw.bcf
bcftools view var.raw.bcf | vcfutils.pl varFilter -D1333 > var.flt.vcf
The filter is based on mpileup output.
E.7.10 Gene prediction with GENESEQER
To analysis gene structures, the program GeneSeqer can be used in the commandline
and as part of a pipeline if necessary. It requires FASTA files and an EST library. First step
is to download protein or mRNA EST files from NCBI. Once that is complete, conversion
of genome annotation and use of GeneSeqer as follows:
gffread -w annotation.file.fa -g /path/to/genome/fasta/chr7.fa \
/path/to/annotation.file.gtf
GeneSeqer -s mouse -f -E est.files.fa -L comparison.files.fa > output
E.7.11 Manipulating files
Merging files uniquely (unique entries in a file):
awk ’!a[$0]++’ ./dir/* > ./new.unique.file
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Separating out strands assuming strand:
#Find strand data column (stringtie gtf, col 7)
awk ’$7 == "-"’ annotation.file.gtf > minus.annot.gtf
awk ’$7 == "+"’ annotation.file.gtf > plus.annot.gtf
This varies on file layout. For instance, BED files normally have strand information in
column 6. If you don’t know where the strand information is at take a peek at it.
cat annotation.file.gtf | head
Use man or -h/--help30 on any Bash function to learn about it’s options.
man cat
head --help | less
awk -h | less
A slightly more complicated usage of awk to export only genes of interest.
awk -F "\t" ’$7 == "+" { print $9 }’ annotation.file.gtf | \
awk -F "; " ’$1 == "gene_id \"MSTRG.2451\""’ > Ube3a.txt
grep -f Ube3a.txt annotation.file.gtf > Ube3a.gtf
The -F option for awk is used to tell the program to look for field separaters similar
to how excel opens up CSV or TSV files. Here, I am telling awk to look for tab sepa-
ration in the forward strand (+) and print the 9th column, which happens to have the
gene information. In stead of dumping it to the screen, I pipe (j) the results into another
awk command to use the ’;’ field separator to extract out all of the "gene_id" labeled as
MSTRG.2451, which is the label StringTie gave Ube3a during assembly. The backslash
(n) is used to comment out the (") as the awk command uses that as part of it’s syntax.
30If using -h/--help, don’t forget to pipe it into less so that you can view it easy. Exit with ’q’.
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Once that is complete (taking only seconds), I direct the output into a new file Ube3a.txt.
The file doesn’t need to already be created to work. As such, it is very easy to overwrite
files if you are not careful.
That all take seconds to run, afterwhich I use the grep command to use the pattern in
the file, (-f), I just created to look in the annotation file and pull out all line-by-line the
’pattern’ in the first file, directing the output to a new file Ube3a.gtf that now has only the
Ube3a annotations. You can edit these smaller files in any text editor (like emacs), while
trying to edit the original annotation.file.gtf would be a nightmare.
Converting GTF files with gffread
Bash isn’t the only way to manipulate files. gffread can be used to convert GTF files
into GFF file format, which is necessary to run MISO.
gffread annotation.file.gtf -o annotation.file.gff
gffread can also be used to convert GTF files into FASTA; however, to convert, an
indexed genome (samtools faidx) is required.
gffread -w Ube3a.fa -g /path/to/chr7.fa Ube3a.gtf
E.7.12 Ballgown
To run Ballgown, StringTie needs to be run a second time for the samples with the -e,
-B, and -G options.
stringtie -p 8 -G /path/to/annotation.gtf -eB \
-o /path/to/output/sample.gtf \
/path/to/sorted/BAM/file.bam
Once run for all the samples, a CSV file is need for importing the data when in R. This
can be done by either editing a new file, in excel or Libre, or printf.
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Running ballgown in R
I personally like using Ballgown [151,328] (version 2.6.0) to look at the average tran-
script expression by tissue. Below is the script to so that. Unfortunately, for the antisense
transcript, the snoRNAs are part of the assembly, so it’s not as informative as one would







#Load phenotype data to generate ballgown object
pheno_unstranded <- read.csv("unstranded.mm9.csv")












For more information on what can be done with ballgown, see the Nature protocol
paper [151].
E.7.13 edgeR
For analysis with edgeR, I have provided a sample script. For more information, the
edgeR manual can be of help. Briefly, the script loads libraries, runs featureCounts, nor-






































group=rep(1:4, each=3),##depend on samples
genes=fc_transcript$annotation)
keep.t <- rowSums(cpm(transcripts) > 1) >= 3 #n=12, 25%





keep.exons <- rowSums(cpm(exons) > 1) >= 3
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exons <- exons[keep.exons, ,keep.lib.sizes=F]
exons <- calcNormFactors(exons)





design <- model.matrix(~group, data=transcripts$sample)
transcripts <- estimateDisp(transcripts, design, robust=TRUE)
exons <- estimateDisp(exons, design, robust=TRUE)
#Testing for DE (One-way Anova like Test)
fit1 <- glmFit(transcripts, design)
fit2 <- glmFit(exons, design)
lrt1 <- glmLRT(fit1, coef=2:4)##depended on design
lrt2 <- glmLRT(fit2, coef=2:4)
sink("DE_transcripts_ANOVA.txt")
print(topTags(lrt1, n = 10000))
sink()
sink("DE_exons_ANOVA.txt")
print(topTags(lrt2, n = 10000))
sink()
##Testing for DE (pairwise)
et1.1 <- exactTest(transcripts, pair=c("2","1"))
et1.2 <- exactTest(transcripts, pair=c("2","3"))
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et1.3 <- exactTest(transcripts, pair=c("2","4"))
et2.1 <- exactTest(exons, pair=c("2","1"))
et2.2 <- exactTest(exons, pair=c("2","3"))
et2.3 <- exactTest(exons, pair=c("2","4"))
sink("DE_transcripts_tissue2VStissue1.csv")
print(topTags(et1.1, n = 10000))
sink()
sink("DE_exons_tissue2VStissue1.csv")
print(topTags(et2.1, n = 10000))
sink()









print(topSpliceDGE(sp, n = 10000))
sink()
E.7.14 Graphic with ggplot2
ggplot2 is a fantastic package for publication quality graphs in R. Everything can
be manipulated for graphic. If you have trouble, there is an active community to help with
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HIGH THROUGHPUT DRUG SCREENING OF MOUSE EMBRYONIC STEM
CELL-DERIVED NEURONS
Summary
High-throughput screening (HTS) to identify new drugs for neurological disorders of-
ten rely on the use of mouse primary neuronal cultures; however, establishing primary
cultures from mice is labor intensive and expensive. Moreover, most HTS facilities do
not allow the use of primary cell lines because of the risks associated with contaminat-
ing other cell lines in the facility. In contrast, embryonic stem (ES) cells are permitted
in most HTS facilities and can be reliable differentiated into neurons, generating an al-
most unlimited source of cells for large-scale studies. Thus, ES cell-derived neurons are
an excellent model system for performing HTS to identify new therapies for neurological
disorders. Here, we developed a high-throughput neuronal culture model via ES cells.
Mouse C57BL/J6 ES cells were successfully differentiated into neurons on poly-d-lysine,
and immunocytochemistry performed using high-throughput imaging system. These re-
sults are promising for the field of neurological disorders and drug discovery.
F.1 Mouse Embryonic Stem Cell Culture (Timing: 5 days)
Mouse embryonic stem (ES) cells are a powerful tool for the scientific discovery be-
cause of their ability of almost endless self-renew and potential to differentiate into mul-
tiple cell types, including neuronal cell types [329]. This pluripotency is a result of the
cell type used to derive ES cells, inner mass of a developing blastocyst. As such, ES cells
are often co-cultured with feeder cells. The pluripotency is facilitated by a complex path-
way involving Wnt/-catenin signaling and cross-talk between Wnt and LIF, leukemia
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inhibitory factor [330, 331]. This replaces the need for inhibition of GSK3, which phos-
phorylates -catenin marking it for ubiquitin-dependent degradation [332, 333], making
LIF an essential factor in culturing self-renewing mouse ES cells [334–336].
F.1.1 Plating feeder cells for co-culture
As mentioned above, ES cells are often co-cultured with feeder cells when being
maintained as self-renewing pluripotent cells. There are a number of feeder cell types to
chose from; however, the most common fibroblasts used as feeder cells are mouse embry-
onic fibroblast (MEF) and SIM mouse embryoderived thioguanine and ouabain resistant
(STO) [337, 338]. In this study, we use a genetically modified versus of the STO cell line,
SNL 76/7, first established by Dr. Allen Bradley [226]. The SNL 76/7 is a unique STO
line as it contains the murine LIF gene; thus, LIF does not need to be added to the culture
media.
1. Coat six 100-mm tissue culture dishes with 0.1% gelatin for SNL adhesion. Add7
ml of gelatin (StemCell Technologies) to each dish and incubate for 30 min at room
temperature.
2. Aspirate the gelatin from the dishes and allow them to dry for 5 min.
3. Culture feeder cells for the ES cells co-culture by plating one vial of Mitomycin
C-inactivated SNL (approx. 2:25 107 cells, 60x concentration) into 60 ml of STO
media (see recipe in Table F.1) and plate onto fixed 100-mm tissue culture dishes.
(a) Quick thaw vial at 37C using a water bath for 3 min
(b) Add to 10 ml of STO media
(c) Centrifuge (<270g for 5 min)
(d) Decant supernatant and resuspend in 60 ml of STO media
(e) Add 10 ml to each plate
(f) Disperse the cells with back and forth motion
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4. Incubate overnight before using (37C, 5% CO2). SNL must be plated at least one
day before adding ES cells. SNL feeder plates are generally good after plating up to
7 days.
F.1.2 Plating ES cells
Expansion of ES cell is important for downstream HTS studies. As such, ES cells
expansion need to be optimized for individual cell-lines. For C57BL/6J ES cells, the
following number of passages is sufficient.
1. Condition one SNL plate with 10 ml of ES media (see recipe in Table F.1 for at
least 2 h before plating ES cells. This allows for LIF expression from the SNL to
be added to the ES media, which is required to maintain ES cell pluripotency and
ability to self-renew.
2. Defrost 1 vial of ES cell, C57BL/6J, (approx. 3:5  106 cells) in 37C water bath
for 3 min. Add to 10 ml of ES media. Transfer to 10 ml of ES media in 15 ml tube
and spin down (<270g for 5 min).
3. Decant supernatant and resuspend in 1 ml of ES media. Add cell suspension of SNL
conditioned plates. Disperse the cells with back and forth motion. Incubate the ES
cells overnight at 37C, 5% CO2.
4. 24 h after plating, ES cells form small colonies, Figure F.1A. Change media with
10 ml of ES media. 48 h after plating, ES cells should be 70-80% confluent, be
careful not to let the ES cells over grow. Condition remaining five SNL plates with
ES media for 2 h. Passage cells.
(a) Aspirate media, and rinse twice with room temperature sterile 1xPBS. Add 2
ml of TrypLE Express (Life Technologies) and incubate for 5 min. Add 3 ml
of ES media to neutralize the trypsin and break the colonies into single cell
suspension. Transfer to sterile 15 ml tube and spin down (<270g, 5 min).
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(b) Aspirate supernatant and gently resuspend in 5 ml of ES media. Add 1 ml of
cell suspension to each conditioned SNL plate. Disperse the cells with back
and forth motion and incubate overnight. Change media next day.
5. 48 h after passaging, ES cells should be 70-80% confluent. These cells are ready for
differentiation.
F.2 Neural Induction (Timing: 7 days)
To induce differentiation of ES cells into neurons, one method is to separate ES cells
from SNL and cultured them in suspension as demonstrated in Figure F.1B. This can be
done one of two ways. The first is several feeder free passages, and the second is by using
gelatin coated flasks to separate the SNL feeder cells from ES cells. For HTS purposes,
the gelatin technique is used. This saves time and resources.
1. Once ES colonies are ready for neural induction (day 6), coat one T175 with 20 ml
of 0.1% gelatin for 30 min at room temperature. Aspirate gelatin and allow it to dry
for 5 min.
2. Aspirate ES media from ES cells, and rinse twice with room temperature sterile
1xPBS. Add 2 ml of TrypLE Express and incubate for 5 min. Add 3 ml of CA
media (see recipe in Table F.1) to neutralize the trypsin and break the colonies into
single cell suspension.
3. Transfer cells suspension to T175 (approx. 25 ml, 5 ml/plate), and incubate for 30
min at 37C, 5% CO2. After incubation, SNL should have attached to the surface
of the gelatin coated flask while the majority of the ES cells should remain floating.
Collect the floating ES cells into 50 ml tube and spin down (<270g, 5 min). Aspirate
supernatant and gently resuspend in 5 ml of CA media.
4. Count the cells using a hemocytometer, or automated cell counter, and plate 4 106
ES cells per 100-mm bacteriological Greiner Petri dishes.
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5. Next day change CA media and split CAs 1:2 by carefully transferring the CA sus-
pension into 50 ml tube (1 plate/tube)1. Let CAs settle for at least 3 min. Remove
supernatant and resuspend CAs gently with 20 ml of CA media. Mix suspension
gently with a 25 ml pipette and plate cells on new dishes.
6. After 48 h in suspension, change CA media as in step 5, however add RA (retinoic
acid) at final concentration of 0.5 mM to CA media. This is another 1:2 split of the
CAs, which may be optional depending on CAs density in suspension. For next four
day change CA media without splitting (2 plates/tube) by resuspending each tube
with 20 ml CA media with 0.5 mM RA.
F.3 Neuron Elongation & Maturation (Timing: 2+ days)
ES cell-derived neurons are traditionally plated on poly-dl-orithine/laminin co-coating
[230–232]. This co-coat is feasible for 24-well format; however, for high-throughput
screening (HTS) purposes poly-d-lysine coated 96- and 384-well plates are more readily
available and less expensive, so we conducted experiments to determine if poly-d-lysine
pre-coated 96-well plates (VWR) could be used for neuron elongation and maturation.
1. (Days Post Differentiation, DPD 0) To dissociate the CAs into single cell suspen-
sion, transfer CAs to 50 ml tubes (2 plates/tube), and wash CAs twice with PBS
before trypsinizing.
(a) Let CAs settle for3 min, then remove supernatant and resuspend CAs gently
with 20 ml of 1x PBS. Let CAs settle again for 3 min, and remove super-
natant. Resuspend CAs gently with 5 ml 1x PBS and let settle for 3 min.
(b) Label and open 1.5/1.6 ml tubes, and carefully transfer CAs at the bottom
of 50 ml tubes into them. Spin down quickly for about 5 s, and carefully
1(1) Splitting CAs is highly depended on number of CAs in suspension, this may vary depending on type
of serum/serum replacement. (2) Do not use narrow pipettes to mix suspension to avoid dissociating the
CAs. (3) By using new plates, this will further remove any lingering SNL feeder cells.
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remove supernatant with pipet tip. Add 1 ml of 0.5% Trypsin-EDTA (Life
Technologies). Vortex and place on heat block for 4 min at 37C rotation and
450 rpm. Vortex the tubes and spin down quickly.
(c) Remove supernatant and resuspend CAs in CA media to neutralize trypsin.
Dissociate CAs by pipetting up and down (approx. 10 times), and spin down
quickly for 5 s. Carefully remove as much supernatant as possible and resus-
pend in N2 media (see recipe in Table F.1), which should be made fresh.
(d) Filter cell suspension through 40 m cell strainer by applying drop by drop2,
and count cells using automated cell counter, or hemocytometer.
2. Plate 9:8 104 cells/well for 96-well plate using sterile hydrospeed in N2 media3.
3. 24 h after plating cells should have attached to the plates as shown in Figure F.1C.
(optional) Change the N2 media to further remove trace amounts of FBS.
4. 48 h after plating N2 media should be changed to Complete media (see recipe in
Table F.1). Add the BDNF, brain derived neurotrophic factor, fresh for long term
cultures of more than three days. Change Complete media every two to three days.
F.4 Representative Results
Figure F.2 shows an outline of the protocol. The first 5 days involves ES cell culture
on SNL feeder cells, which is highly depended on cell lines growth. Following ES cell
culture and expansion, the ES cells are separated from the SNL feeder cells expressing
LIF to initiate the differentiation process. For high-throughput purposes, cells were grown
in suspension and split to avoid overcrowding and obtain optimal numbers. In this case,
one vial of ES cells generated 15-20 plates worth of 4 106 cells, which are split twice
generating four times the initial number of cells. After neuronal induction, the cellular
aggregates are dissociated and placed into serum free N2 media for 48 h. After which, the
2Avoid applying pressure.
3Plating density should be optimized for ES cell lines.
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Figure F.1: Differentiation of ES cells into neurons. Light microscope images of A) co-
cultures of ES cells and SNL feeder cells at 40x magnification, B) embryoid boides in
suspension at 20x magnification, and C) elongated neurons after three days of culture at
20x magnification.
.
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Figure F.2: Timeline for the differentiation of ES cells into neurons.
cells are changed to the Complete media for long term maintenance, with BDNF added
to support neuronal growth for cultures lasting more than five days. Figure F.3 shows ES
cell-derived neurons that have been cultured for twelve days.
F.5 Discussion
Here, a high-throughput screening method optimized for drug discovery in neuronal
cultures is described. For HTS purposes, a large initial number of ES cells is essential;
therefore, each individual ES cell-line must be optimized for cell growth. In this method,
the use of SNL 76/7 feeder cells is recommended as these cells secrete LIF - supplement
required to maintain undifferentiated ES cell state - into the media eliminating the addi-
tional purchase of LIF.
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.Nestin Map2 Doublecortin Tubulin III
Figure F.3: High-throughput screening immunofluorescence characterization of differen-
tiated ES cells in 96-well format at day 12, 10x magnification.
For neuronal cultures including ES cell-derived neurons, neural connectivity patterns
are crucial for proper function and development. For HTS assays, this adds an additional
requirement for an extracellular matrix coating at the bottom of the wells for proper cell
attachment and growth [339–341]. As such, extra cellular signaling proteins like laminin
are needed. The majority of ES cell-derived neuron protocols utilize a co-coat with laminin
[230, 232]; however, in these protocols the co-coating is applied by hand, which is not
conductive to HTS. Furthermore, ordering optical-bottom, sterile plates with a laminin co-
coat for 96- or 384-well plates is an expensive special order process that can take upwards
to three months.
For those reasons, an alternative solution of using a single coating of poly-d-lysine
was choice for this protocol. Poly-d-lysine promotes cell adhesion through ionic interac-
tions [339]. Moreover, poly-d-lysine is a common substrate choice for culturing primary
neurons [180]. In this protocol, we successfully differentiate ES cells into neurons on
poly-d-lysine, to the best of our knowledge, for the first time.
Finally, this protocol provides an efficient approach for large-scale differentiation of
ES cells into neurons. More importantly, the methods offers a platform for drug discovery
for single gene neurological disorders that have mouse models currently available like
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Angelman syndrome - a severe neurodevelopmental disorder. The power of using ES
cells to derive neuron cultures extend beyond the world of drug discovery, especially with
the advances in gene manipulation technology (i.e. CRISPR/Cas9 systems), where ES
cells can be manipulated in culture before being expanded and differentiated into neurons
to answer basic questions in the field of neuroscience. Altogether, this method has the









7. 100-mm Petri dishes
8. 15 ml & 50 ml conical tubes
9. 1.6 ml tubes
10. Bacteriological Petri dishes
11. 40 m nylon cell strainer
12. Sterile filter 0.2 m
13. Poly-d-lysine 96-well pre-coated plates
4All reagents and materials used must be sterile.
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Table F.1: Media composition - Full




































Media Components Company Cat. # Notes
































Progesterone P8783-1G 20 nM
Putrescence P5780-5G 100 nM
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Table F.1: Continued...
Media Components Company Cat. # Notes













GlutaMAX 35050061 2 mM
B27 17504044 1%
BDNF PHC7074 50 ng/ml

















Table F.2: List of Antibodies
Antibody Company Cat. # Dilution
anti-Nestin EMD Millipore AB5922 1:200
anti-Map2 Santa Cruz sc-20172 1:250
anti-DCx Biotechnology sc-8066 1:200
anti-mouse (555, Cy3) Jackson Immuno 115-165-146 1:200
anti-rabbit (488, Cy2) 111-545-144 1:200
anti-TOPRO-3 Life Technologies T3605 1:1000
anti-Tubulin III Sigma-Aldrich T5076 1:200
anti-Goat Serum G9023-10ML 5%
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